1
|
Fouda RT, Cherukury HM, Kiven SB, Garcia NR, Argueta DA, Velasco GJ, Gupta K, Roberts JD. Colchicine reduces inflammation in a humanized transgenic murine model of sickle cell disease. Haematologica 2024; 109:308-311. [PMID: 37534545 PMCID: PMC10772532 DOI: 10.3324/haematol.2023.283377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Accepted: 07/28/2023] [Indexed: 08/04/2023] Open
Abstract
Not available.
Collapse
Affiliation(s)
- Raghda T Fouda
- Hematology/Oncology, Department of Medicine, University of California, Irvine, CA
| | - Hemanth M Cherukury
- Hematology/Oncology, Department of Medicine, University of California, Irvine, CA
| | - Stacy B Kiven
- Hematology/Oncology, Department of Medicine, University of California, Irvine, CA
| | - Natalie R Garcia
- Hematology/Oncology, Department of Medicine, University of California, Irvine, CA
| | - Donovan A Argueta
- Hematology/Oncology, Department of Medicine, University of California, Irvine, CA
| | - Graham J Velasco
- Pathology Department, VA Long Beach Medical Center, Long Beach, CA
| | - Kalpna Gupta
- Hematology/Oncology, Department of Medicine, University of California, Irvine, CA, USA; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.
| | | |
Collapse
|
2
|
Roberts JD. Surgery or Endovascular Therapy for Chronic Limb Ischemia. N Engl J Med 2023; 388:e37. [PMID: 36920767 DOI: 10.1056/nejmc2300713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/16/2023]
|
3
|
Curtis SA, Balbuena-Merle R, Roberts JD, Hendrickson JE, Joanna S, Devine L, DeVeaux M, Zselterman D, Brandow AM. Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfus Apher Sci 2022; 61:103304. [PMID: 34782244 PMCID: PMC9838733 DOI: 10.1016/j.transci.2021.103304] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Revised: 10/05/2021] [Accepted: 10/28/2021] [Indexed: 01/18/2023]
Abstract
BACKGROUND Chronic red blood cell transfusions reduce acute care utilization for sickle cell disease (SCD) pain. However, little is known about whether chronic transfusions treat or prevent the development of non-crisis pain. We investigated patient-report of pain in adults with SCD receiving chronic exchange transfusions (CET) compared to adults not on CET with similar disease characteristics. STUDY METHOD AND DESIGN Eleven participants receiving chronic exchange transfusion (CET) for at least one year were compared to 33 participants not receiving CET. Participants completed validated patient-reported outcomes regarding pain impact and quality of life at regularly scheduled visits or before CET. One year of health care utilization and opioid prescriptions were examined. RESULTS After 1:1 propensity matching was performed for age, genotype, WBC and neutrophil counts, patients on CET had lower Pain Impact scores (-5.1, p = 0.03) and higher Neuropathic (7.4, p < 0.001) and Nociceptive Pain Quality (3.7, p < 0.001) scores, all indicating worse pain. However, CET was associated with a reduction in annual all cause admissions (-3.1, p < 0.001), length of stay (-2.1 days, p < 0.001) and ED visits (-2.7, p < 0.001). CET was not associated with differences in opioids dispensed. CONCLUSIONS After adjusting for disease characteristics, CET was associated with worse pain impact and neuropathic and nociceptive pain quality, lower health care utilization and with similar levels of opioids dispensed. This data suggest that CET may reduce hospitalizations for acute pain but may not adequately treat nociceptive or neuropathic pain in SCD.
Collapse
Affiliation(s)
| | | | - John D Roberts
- Yale Cancer Center, Yale School of Medicine CT, United States
| | | | - Starrels Joanna
- Division of General Internal Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States
| | - Lesley Devine
- Yale Cancer Center, Yale School of Medicine CT, United States
| | | | | | | |
Collapse
|
4
|
Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leuk Lymphoma 2020; 62:1187-1194. [PMID: 33356689 DOI: 10.1080/10428194.2020.1861270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
We report the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia or MDS or CML with blast crisis. Thirty-eight patients received IV belinostat days 1-5 and 8-12 with IV bortezomib days 1, 4, 8, and 11 every 21 days. QTc prolongation was the only identified DLT. The RP2Ds were 1.3 mg/m2 bortezomib and 1000 mg/m2 belinostat. One patient with highly refractory MLL-ENL rearranged biphenotypic AML with multiple karyotypic aberrations had a complete pathologic and karyotypic response. One patient with post-MPN AML remained on study with stable disease (SD) for 32 cycles. Whole-exome sequencing revealed no aberrations in the first patient and a hyper-mutator genotype in the second. Eighteen patients had a best response of SD. We conclude that this treatment strategy is feasible but has limited activity in this population. Nevertheless, the factors that predict exceptional responses to this strategy warrant further investigation.
Collapse
Affiliation(s)
- Beata Holkova
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.,Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
| | - Danielle Shafer
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.,Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
| | - Victor Yazbeck
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.,Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
| | - Sandeep Dave
- Department of Medicine, Duke University, Durham, NC, USA
| | - Prithviraj Bose
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.,Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
| | - Mary Beth Tombes
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
| | - Ellen Shrader
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
| | - Wen Wan
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.,Department of Statistics, Virginia Commonwealth University, Richmond, VA, USA
| | - Dipankar Bandyopadhyay
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.,Department of Statistics, Virginia Commonwealth University, Richmond, VA, USA
| | - Caryn Weir
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
| | | | - Amanda Garnett
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
| | - Maciej Kmieciak
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
| | - John D Roberts
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.,Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
| | | | - Steven Grant
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.,Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.,Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA.,Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA.,The Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA
| |
Collapse
|
5
|
Curtis SA, Brandow AM, DeVeaux M, Zeltermam D, Devine L, Roberts JD. Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints. Cannabis Cannabinoid Res 2020; 5:255-262. [PMID: 32923662 DOI: 10.1089/can.2019.0036] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Introduction: Previous studies have shown that cannabis use is common in adults with sickle cell disease (SCD), and that many patients report using cannabis to treat pain. Methods: We performed a cross-sectional study of adults with SCD and compared daily users of cannabis with others using validated patient-reported measures of pain and quality of life as well as opioid and health care utilization. Results: Daily cannabis users with SCD had worse pain episode severity scores than others (56.7 vs. 48.8, p=0.02) yet had 1.8 fewer annual admissions (p=0.01) and 1.2 fewer annual emergency room (ER) visits (p=0.01), and similar amounts of opioids dispensed to others after matching for age, gender, SCD genotype, hydroxyurea use, and pain impact scores. Conclusions: We show that people with SCD with more severe pain crisis are more likely to use daily cannabis, yet have lower rates of hospital admission and ER use as compared with others with similar disease severity and pain impact. Randomized controlled trials should be performed.
Collapse
Affiliation(s)
- Susanna A Curtis
- Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
| | - Amanda M Brandow
- Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - Michelle DeVeaux
- Department of Early Clinical Development, Regeneron Pharmaceuticals, Tarrytown, New York
| | - Daniel Zeltermam
- Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut
| | - Lesley Devine
- Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
| | - John D Roberts
- Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
| |
Collapse
|
6
|
Rousseau R, Weisberg DF, Gorero J, Parwani V, Bozzo J, Kenyon K, Smith C, Cole J, Curtis S, Forray A, Roberts JD. Utilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program. PLoS One 2020; 15:e0236360. [PMID: 32706825 PMCID: PMC7380627 DOI: 10.1371/journal.pone.0236360] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Accepted: 07/03/2020] [Indexed: 11/30/2022] Open
Abstract
In 2011 Yale New Haven Hospital, in response to high utilization of acute care services and widespread patient and health care personnel dissatisfaction, set out to improve its care of adults living with sickle cell disease. Re-organization components included recruitment of additional personnel; re-locating inpatients to a single nursing unit; reducing the number of involved providers; personalized care plans for pain management; setting limits upon access to parenteral opioids; and an emphasis upon clinic visits focused upon home management of pain as well as specialty and primary care. Outcomes included dramatic reductions in inpatient days (79%), emergency department visits (63%), and hospitalizations (53%); an increase in outpatient visits (31%); and a decrease in costs (49%). Providers and nurses viewed the re-organization and outcomes positively. Most patients reported improvements in pain control and life style; many patients thought the re-organization process was unfair. Their primary complaint was a lack of shared decision-making. We attribute the contrast in these perspectives to the inherent difficulties of managing recurrent acute and chronic pain with opioids, especially within the context of the imbalance in wellness, power, and privilege between persons living with sickle cell disease, predominantly persons of color and poor socio-economic status, and health care organizations and their personnel.
Collapse
Affiliation(s)
- Robert Rousseau
- Northeastern University Bouvé College of Health Sciences, Boston, MA, United States of America
| | - Daniel F. Weisberg
- Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Jack Gorero
- Hartford Hospital, Hartford, CT, United States of America
| | - Vivek Parwani
- Yale School of Medicine, New Haven, CT, United States of America
| | - Janis Bozzo
- Yale New Haven Health, New Haven, CT, United States of America
| | - Kathleen Kenyon
- Yale New Haven Hospital, New Haven, CT, United States of America
| | - Constance Smith
- Yale New Haven Hospital, New Haven, CT, United States of America
| | - Joanna Cole
- Yale New Haven Hospital, New Haven, CT, United States of America
| | - Susanna Curtis
- Yale School of Medicine, New Haven, CT, United States of America
| | - Ariadna Forray
- Yale School of Medicine, New Haven, CT, United States of America
| | - John D. Roberts
- Yale School of Medicine, New Haven, CT, United States of America
- * E-mail:
| |
Collapse
|
7
|
Qin Y, Grimm SA, Roberts JD, Chrysovergis K, Wade PA. Alterations in promoter interaction landscape and transcriptional network underlying metabolic adaptation to diet. Nat Commun 2020; 11:962. [PMID: 32075973 PMCID: PMC7031266 DOI: 10.1038/s41467-020-14796-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Accepted: 01/27/2020] [Indexed: 02/08/2023] Open
Abstract
Metabolic adaptation to nutritional state requires alterations in gene expression in key tissues. Here, we investigated chromatin interaction dynamics, as well as alterations in cis-regulatory loci and transcriptional network in a mouse model system. Chronic consumption of a diet high in saturated fat, when compared to a diet high in carbohydrate, led to dramatic reprogramming of the liver transcriptional network. Long-range interaction of promoters with distal regulatory loci, monitored by promoter capture Hi-C, was regulated by metabolic status in distinct fashion depending on diet. Adaptation to a lipid-rich diet, mediated largely by nuclear receptors including Hnf4α, relied on activation of preformed enhancer/promoter loops. Adaptation to carbohydrate-rich diet led to activation of preformed loops and to de novo formation of new promoter/enhancer interactions. These results suggest that adaptation to nutritional changes and metabolic stress occurs through both de novo and pre-existing chromatin interactions which respond differently to metabolic signals. Metabolic adaptation to different diets results in changes to gene expression. Here, the authors characterise the chromatin landscape and transcriptional network in mice on a diet of high saturated fat, compared to a diet high in carbohydrate, finding a dramatic reprogramming of the liver transcriptional network.
Collapse
Affiliation(s)
- Yufeng Qin
- Eukaryotic Transcriptional Regulation Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Sara A Grimm
- Integrative Bioinformatics Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - John D Roberts
- Eukaryotic Transcriptional Regulation Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Kaliopi Chrysovergis
- Eukaryotic Transcriptional Regulation Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Paul A Wade
- Eukaryotic Transcriptional Regulation Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA.
| |
Collapse
|
8
|
Weiss K, Lazar HP, Kurolap A, Martinez AF, Paperna T, Cohen L, Smeland MF, Whalen S, Heide S, Keren B, Terhal P, Irving M, Takaku M, Roberts JD, Petrovich RM, Vergano SAS, Kenney A, Hove H, DeChene E, Quinonez SC, Colin E, Ziegler A, Rumple M, Jain M, Monteil D, Roeder ER, Nugent K, van Haeringen A, Gambello M, Santani A, Medne L, Krock B, Skraban CM, Zackai EH, Dubbs HA, Smol T, Ghoumid J, Parker MJ, Wright M, Turnpenny P, Clayton-Smith J, Metcalfe K, Kurumizaka H, Gelb BD, Feldman HB, Campeau PM, Muenke M, Wade PA, Lachlan K. Correction: The CHD4-related syndrome: a comprehensive investigation of the clinical spectrum, genotype–phenotype correlations, and molecular basis. Genet Med 2019; 22:669. [DOI: 10.1038/s41436-019-0727-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
9
|
Abstract
PURPOSE A novel strategy for management of acute pain associated with sickle cell disease (SCD), referred to as the oral tier approach, is described. SUMMARY SCD is an inherited blood disorder characterized by episodic acute pain known as vaso-occlusive crisis (VOC), which is the most common reason for emergency department visits and hospital admissions in patients with SCD; these patients are often treated with parenteral opioids on admission and then transitioned to oral opioids prior to discharge. In this report, experience with use of the oral tier approach in 3 patients with SCD hospitalized for management of VOC is reported. As per usual practice, acute pain was initially managed with parenteral opioids via patient-controlled analgesia (PCA). Once pain control was established, an oral tier was added. The oral tier consisted of 3 orders. The first order was for an oral opioid, to be administered every 3 hours on a scheduled basis; however, the patient could refuse 1 or more of these scheduled doses. Two additional orders specified that the patients could receive additional oral opioids in incremental doses for moderate (grade 4-7) or severe (grade 8-10) pain if appropriate. To facilitate transition to an oral regimen with which the patients might be discharged, they were encouraged to use oral opioids in preference to parenteral opioids. Opioid usage and average daily pain scores for the 3 patients are reported. CONCLUSION Healthcare providers can use the oral tier approach to facilitate rapid inpatient conversion from i.v. PCA to oral opioids while providing adequate pain control in patients with SCD who develop VOC.
Collapse
Affiliation(s)
| | - Francis J Zamora
- Department of Pharmacy Services, Yale New Haven Hospital, New Haven, CT
| | | |
Collapse
|
10
|
Smith WR, McClish DK, Roberts JD, Kandalaft O, Dahman B, Knisely J, Levenson J, Roseff S, Aisiku IP. Prescription Opioid Misuse Index in sickle cell patients: A brief questionnaire to assess at-risk for opioid abuse. J Opioid Manag 2019; 15:323-331. [PMID: 31637684 DOI: 10.5055/jom.2019.0517] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To develop a survey instrument to identify adult sickle cell disease (SCD) patients on chronic opioid therapy who are at-risk for opioid abuse. DESIGN Prospective survey and interview. SETTING Adult SCD clinic in a large urban teaching facility. PATIENTS/PARTICIPANTS Convenience sampling of adult patients presenting to the sickle cell clinic. INTERVENTIONS None. MAIN OUTCOME Primary outcome was "at-risk for opioid misuse," defined as at least 3/8 "yes" answers (a positive composite score) on the Prescription Opioid Misuse Index (POMI) questionnaire. Secondary outcome was DSM-IV criteria for substance abuse using the DSM IV Diagnostic Interview Schedule. RESULTS Of the 99 patients who completed the POMI, the mean age was 36 years; 58.6 percent were female, 48 percent were hemoglobin SS (47/99), and 26 percent were SC (26/99). Twenty-four percent (24/99) were identified as at-risk for opioid misuse using the POMI. There were no differences in demographic, SCD genotype, or socioeconomic variables for at-risk versus not-at-risk patients. CONCLUSION Twenty-four percent of unselected adult SCD patients on opioids were identified as at-risk for opioid misuse using a quick survey. This may represent as much as 2.5-7 times the national misuse rate. This group of patients may benefit from additional diagnostic and therapeutic interventions to help understand and manage their opioid usage.
Collapse
Affiliation(s)
- Wally R Smith
- Professor, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia
| | - Donna K McClish
- Professor, Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia
| | - John D Roberts
- Professor, Department of Medicine, Yale University, New Haven, Connecticut
| | - Osama Kandalaft
- Department of Internal Medicine, Baystate Medical Center, Springfield, Massachusetts
| | - Bassam Dahman
- Assistant Professor, Department of Healthcare Policy and Research, Virginia Commonwealth University, Richmond, Virginia
| | - Janet Knisely
- Associate Professor, Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia
| | - James Levenson
- Professor, Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia
| | - Susan Roseff
- Professor, Department of Pathology, Virginia Commonwealth University, Richmond, Virginia
| | - Imo P Aisiku
- Assistant Professor, Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts
| |
Collapse
|
11
|
Weiss K, Lazar HP, Kurolap A, Martinez AF, Paperna T, Cohen L, Smeland MF, Whalen S, Heide S, Keren B, Terhal P, Irving M, Takaku M, Roberts JD, Petrovich RM, Schrier Vergano SA, Kenney A, Hove H, DeChene E, Quinonez SC, Colin E, Ziegler A, Rumple M, Jain M, Monteil D, Roeder ER, Nugent K, van Haeringen A, Gambello M, Santani A, Medne L, Krock B, Skraban CM, Zackai EH, Dubbs HA, Smol T, Ghoumid J, Parker MJ, Wright M, Turnpenny P, Clayton-Smith J, Metcalfe K, Kurumizaka H, Gelb BD, Baris Feldman H, Campeau PM, Muenke M, Wade PA, Lachlan K. The CHD4-related syndrome: a comprehensive investigation of the clinical spectrum, genotype-phenotype correlations, and molecular basis. Genet Med 2019; 22:389-397. [PMID: 31388190 DOI: 10.1038/s41436-019-0612-0] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Accepted: 07/09/2019] [Indexed: 12/13/2022] Open
Abstract
PURPOSE Sifrim-Hitz-Weiss syndrome (SIHIWES) is a recently described multisystemic neurodevelopmental disorder caused by de novo variants inCHD4. In this study, we investigated the clinical spectrum of the disorder, genotype-phenotype correlations, and the effect of different missense variants on CHD4 function. METHODS We collected clinical and molecular data from 32 individuals with mostly de novo variants in CHD4, identified through next-generation sequencing. We performed adenosine triphosphate (ATP) hydrolysis and nucleosome remodeling assays on variants from five different CHD4 domains. RESULTS The majority of participants had global developmental delay, mild to moderate intellectual disability, brain anomalies, congenital heart defects, and dysmorphic features. Macrocephaly was a frequent but not universal finding. Additional common abnormalities included hypogonadism in males, skeletal and limb anomalies, hearing impairment, and ophthalmic abnormalities. The majority of variants were nontruncating and affected the SNF2-like region of the protein. We did not identify genotype-phenotype correlations based on the type or location of variants. Alterations in ATP hydrolysis and chromatin remodeling activities were observed in variants from different domains. CONCLUSION The CHD4-related syndrome is a multisystemic neurodevelopmental disorder. Missense substitutions in different protein domains alter CHD4 function in a variant-specific manner, but result in a similar phenotype in humans.
Collapse
Affiliation(s)
- Karin Weiss
- The Genetics Institute, Rambam Health Care Campus, Haifa, Israel.
| | - Hayley P Lazar
- Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
| | - Alina Kurolap
- The Genetics Institute, Rambam Health Care Campus, Haifa, Israel.,The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Ariel F Martinez
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Tamar Paperna
- The Genetics Institute, Rambam Health Care Campus, Haifa, Israel
| | - Lior Cohen
- Genetics Institute, Schneider Children's Medical Center, Petah Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Marie F Smeland
- Department of Medical Genetics, University Hospital of North Norway, Tromsø, Norway
| | - Sandra Whalen
- UF de génétique clinique, Centre de Référence Maladies Rares des Anomalies du développement et syndromes malformatifs, APHP, Hôpital Trousseau, Paris, France
| | - Solveig Heide
- AP-HP, Département de Génétique, Centre de Référence Maladies Rares "Anomalies du développement et syndromes malformatifs" Hôpital de la Pitié Salpêtrière, Paris, France
| | - Boris Keren
- AP-HP, Département de Génétique, Centre de Référence Maladies Rares "Anomalies du développement et syndromes malformatifs" Hôpital de la Pitié Salpêtrière, Paris, France
| | - Pauline Terhal
- Department of Genetics, Utrecht University Medical Center, Utrecht, the Netherlands
| | - Melita Irving
- Department of Clinical Genetics, Guy's Hospital, London, UK
| | - Motoki Takaku
- Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
| | - John D Roberts
- Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
| | - Robert M Petrovich
- Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
| | - Samantha A Schrier Vergano
- Division of Medical Genetics and Metabolism, Children's Hospital of The King's Daughters, Norfolk, VA, USA.,Department of Pediatrics, Eastern Virginia Medical School, Norfolk, VA, USA
| | - Amy Kenney
- Division of Medical Genetics and Metabolism, Children's Hospital of The King's Daughters, Norfolk, VA, USA
| | - Hanne Hove
- Centre for Rare Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Elizabeth DeChene
- Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Shane C Quinonez
- Department of Pediatrics, Division of Genetics, Metabolism and Genomic Medicine, University of Michigan, Ann Arbor, MI, USA
| | - Estelle Colin
- Department of Biochemistry and Genetics, University Hospital Angers, Angers, France
| | - Alban Ziegler
- Department of Biochemistry and Genetics, University Hospital Angers, Angers, France
| | | | - Mahim Jain
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.,Bone and Osteogenesis Imperfecta Department, Kennedy Krieger Institute, Baltimore, MD, USA
| | - Danielle Monteil
- Department of Pediatrics, Naval Medical Center Portsmouth, Portsmouth, VA, USA
| | - Elizabeth R Roeder
- Departments of Pediatrics and Molecular and Human Genetics, Baylor College of Medicine, San Antonio, TX, USA
| | - Kimberly Nugent
- Departments of Pediatrics and Molecular and Human Genetics, Baylor College of Medicine, San Antonio, TX, USA
| | - Arie van Haeringen
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Michael Gambello
- Department of Human Genetics, School of Medicine, Emory University, Atlanta, GA, USA
| | - Avni Santani
- Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Līvija Medne
- Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Bryan Krock
- Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Cara M Skraban
- Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Elaine H Zackai
- Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Holly A Dubbs
- Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Thomas Smol
- Department of Clinical Genetics, Lille University Hospital, CHU Lille, Lille, France.,EA7364 RADEME (Research Team on Rare Developmental and Metabolic Diseases), Lille 2 University, Lille, France
| | - Jamal Ghoumid
- Department of Clinical Genetics, Lille University Hospital, CHU Lille, Lille, France.,EA7364 RADEME (Research Team on Rare Developmental and Metabolic Diseases), Lille 2 University, Lille, France
| | - Michael J Parker
- Sheffield Children's Hospital NHS Foundation Trust, Western Bank, Sheffield, UK
| | - Michael Wright
- Northern Genetics Service, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Institute of Human Genetics, International Centre for Life, Newcastle upon Tyne, UK
| | - Peter Turnpenny
- University of Exeter Medical School, Clinical Genetics Royal Devon & Exeter Hospital, Exeter, UK
| | - Jill Clayton-Smith
- Institute of Evolution, Systems and Genomics, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.,Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK
| | - Kay Metcalfe
- Institute of Evolution, Systems and Genomics, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.,Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK
| | - Hitoshi Kurumizaka
- Laboratory of Structural Biology, Graduate School of Advanced Science & Engineering, Waseda University, Tokyo, Japan
| | - Bruce D Gelb
- Mindich Child Health and Development Institute and Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Hagit Baris Feldman
- The Genetics Institute, Rambam Health Care Campus, Haifa, Israel.,The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Philippe M Campeau
- Department of Pediatrics, University of Montreal and CHU Sainte-Justine, Montreal, QC, Canada
| | - Maximilian Muenke
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Paul A Wade
- Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
| | - Katherine Lachlan
- Wessex Clinical Genetics Service, University Hospital Southampton NHS Trust. Department of Human Genetics and Genomic Medicine, Southampton University, Southampton, UK
| |
Collapse
|
12
|
Balbuena-Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CJ, Tormey CA, Siddon AJ, Roberts JD, Hendrickson JE. Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease. Transfusion 2019; 59:3219-3227. [PMID: 31355970 DOI: 10.1111/trf.15463] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Revised: 05/25/2019] [Accepted: 07/05/2019] [Indexed: 12/14/2022]
Abstract
BACKGROUND Despite the clinical significance of red blood cell (RBC) alloantibodies, there are currently no laboratory tests available to predict which patients may be at risk of antibody formation after transfusion exposure. Given their phagocytic and inflammatory functions, we hypothesized that differences in circulating monocytes may play a role in alloimmunization. STUDY DESIGN AND METHODS Forty-two adults with sickle cell disease (SCD) were recruited, with data extracted from the electronic medical record and peripheral blood analyzed by flow cytometry for total monocytes, monocyte subsets (CD14 high/CD16 low+ classical monocytes, CD14 high/CD16 high+ intermediate monocytes, and CD14 intermediate/CD16 high+ non-classical/inflammatory monocytes), and FcγR1 (CD64) expression. Thirteen "non-responder" patients (non-alloimmunized patients with documented RBC transfusion at the study institution) were compared to 20 alloimmunized "responder" patients, who had a total of 44 RBC alloantibodies identified. RESULTS There were no significant differences in the percentages of total monocytes, monocyte subsets, or measured cytokines between non-responders and responders. However, non-responders had higher CD64 expression on classical monocytes (MFI mean 3424 ± standard deviation 1141) compared to responders (MFI mean 2285 ± 1501), p = 0.029, and on intermediate monocytes (MFI mean 3720 ± 1191) compared to responders (MFI mean 2497 ± 1640), p = 0.033. CONCLUSIONS Monocytes and the inflammatory milieu increasingly are being appreciated to play a role in some complications of SCD. The differences in FcγR1 expression on monocyte subsets noted between responders and non-responders, which cannot be directly explained by the serum cytokines evaluated, warrant further investigation.
Collapse
Affiliation(s)
| | - Susanna A Curtis
- Division of Hematology/Oncology, Yale University, New Haven, Connecticut
| | - Lesley Devine
- Department of Laboratory Medicine, Yale University, New Haven, Connecticut
| | - David R Gibb
- Department of Laboratory Medicine, Yale University, New Haven, Connecticut
| | - Matthew S Karafin
- Medical Sciences Institute, Blood Center of Wisconsin, part of Versiti, Milwaukee, WI.,Department of Pathology, Medical College of Wisconsin, Milwaukee, WI
| | - Chance John Luckey
- Department of Pathology, University of Virginia, Charlottesville, Virginia
| | - Christopher A Tormey
- Department of Laboratory Medicine, Yale University, New Haven, Connecticut.,VA Connecticut, Pathology and Laboratory Medicine Service, West Haven, Connecticut
| | - Alexa J Siddon
- Department of Laboratory Medicine, Yale University, New Haven, Connecticut.,VA Connecticut, Pathology and Laboratory Medicine Service, West Haven, Connecticut.,Department of Pathology, Yale University, New Haven, Connecticut
| | - John D Roberts
- Division of Hematology/Oncology, Yale University, New Haven, Connecticut
| | - Jeanne E Hendrickson
- Department of Laboratory Medicine, Yale University, New Haven, Connecticut.,Department of Pediatrics, Yale University, New Haven, Connecticut
| |
Collapse
|
13
|
Snijders Blok L, Rousseau J, Twist J, Ehresmann S, Takaku M, Venselaar H, Rodan LH, Nowak CB, Douglas J, Swoboda KJ, Steeves MA, Sahai I, Stumpel CTRM, Stegmann APA, Wheeler P, Willing M, Fiala E, Kochhar A, Gibson WT, Cohen ASA, Agbahovbe R, Innes AM, Au PYB, Rankin J, Anderson IJ, Skinner SA, Louie RJ, Warren HE, Afenjar A, Keren B, Nava C, Buratti J, Isapof A, Rodriguez D, Lewandowski R, Propst J, van Essen T, Choi M, Lee S, Chae JH, Price S, Schnur RE, Douglas G, Wentzensen IM, Zweier C, Reis A, Bialer MG, Moore C, Koopmans M, Brilstra EH, Monroe GR, van Gassen KLI, van Binsbergen E, Newbury-Ecob R, Bownass L, Bader I, Mayr JA, Wortmann SB, Jakielski KJ, Strand EA, Kloth K, Bierhals T, Roberts JD, Petrovich RM, Machida S, Kurumizaka H, Lelieveld S, Pfundt R, Jansen S, Deriziotis P, Faivre L, Thevenon J, Assoum M, Shriberg L, Kleefstra T, Brunner HG, Wade PA, Fisher SE, Campeau PM. Author Correction: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language. Nat Commun 2019; 10:2079. [PMID: 31048695 PMCID: PMC6497626 DOI: 10.1038/s41467-019-10161-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Affiliation(s)
- Lot Snijders Blok
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.,Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, 6500AH, The Netherlands.,Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands
| | - Justine Rousseau
- CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada
| | - Joanna Twist
- National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
| | - Sophie Ehresmann
- CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada
| | - Motoki Takaku
- National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
| | - Hanka Venselaar
- Centre for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands
| | - Lance H Rodan
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA
| | - Catherine B Nowak
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA
| | - Jessica Douglas
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA
| | - Kathryn J Swoboda
- Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
| | - Marcie A Steeves
- Department of Medical Genetics, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Inderneel Sahai
- Department of Medical Genetics, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Connie T R M Stumpel
- Department of Clinical Genetics and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, 6202AZ, The Netherlands
| | - Alexander P A Stegmann
- Department of Clinical Genetics and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, 6202AZ, The Netherlands
| | | | - Marcia Willing
- Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Elise Fiala
- Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA
| | | | - William T Gibson
- British Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada.,Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada
| | - Ana S A Cohen
- British Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada.,Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada
| | - Ruky Agbahovbe
- British Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada.,Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada
| | - A Micheil Innes
- Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada
| | - P Y Billie Au
- Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada
| | - Julia Rankin
- Department of Clinical Genetics, Royal Devon and Exeter NHS Foundation Trust (Heavitree), Exeter, EX2 5DW, UK
| | - Ilse J Anderson
- Division of Genetics, Department of Medicine, University of Tennessee Medical Center, Knoxville, TN 37920, USA
| | | | | | | | - Alexandra Afenjar
- GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris ; Department of Medical Genetics and Centre de Référence Malformations et maladies congénitales du cervelet et déficiences intellectuelles de causes rares, Armand Trousseau Hospital, GHUEP, AP-HP, Paris, 75012, France
| | - Boris Keren
- AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, 75013, France.,Groupe de Recherche Clinique (GRC) 'déficience intellectuelle et autisme' UPMC, Paris, 75005, France
| | - Caroline Nava
- AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, 75013, France.,Groupe de Recherche Clinique (GRC) 'déficience intellectuelle et autisme' UPMC, Paris, 75005, France.,INSERM, U 1127, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, 75013, Paris, France
| | - Julien Buratti
- AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, 75013, France
| | - Arnaud Isapof
- GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris 06; Department Child Neurology and Reference Center for Neuromuscular Diseases "Nord/Est/Ile-de-France", FILNEMUS, Armand Trousseau Hospital, GHUEP, AP-HP, Paris, 75012, France
| | - Diana Rodriguez
- GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris 06; Department of Child Neurology and National Reference Center for Neurogenetic Disorders, Armand Trousseau Hospital, GHUEP, AP-HP, INSERM U1141, 75012, Paris, France
| | - Raymond Lewandowski
- Clinical Genetics Division, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
| | - Jennifer Propst
- Clinical Genetics Division, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
| | - Ton van Essen
- Clinical Genetics Department, University Medical Center Groningen, Groningen, 9700RB, The Netherlands
| | - Murim Choi
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 08826, Republic of Korea
| | - Sangmoon Lee
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 08826, Republic of Korea
| | - Jong H Chae
- Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children's Hospital, Seoul, 08826, Republic of Korea
| | - Susan Price
- Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7HE, UK
| | | | | | | | - Christiane Zweier
- Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany
| | - André Reis
- Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany
| | - Martin G Bialer
- Northwell Health, Division of Medical Genetics and Genomics, Great Neck, NY 11021, USA
| | - Christine Moore
- Northwell Health, Division of Medical Genetics and Genomics, Great Neck, NY 11021, USA
| | - Marije Koopmans
- Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, 3508AB, The Netherlands
| | - Eva H Brilstra
- Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, 3508AB, The Netherlands
| | - Glen R Monroe
- Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, 3508AB, The Netherlands
| | - Koen L I van Gassen
- Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, 3508AB, The Netherlands
| | - Ellen van Binsbergen
- Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, 3508AB, The Netherlands
| | - Ruth Newbury-Ecob
- University Hospitals Bristol, Department of Clinical Genetics, St Michael's Hospital, Bristol, BS2 8EG, UK
| | - Lucy Bownass
- University Hospitals Bristol, Department of Clinical Genetics, St Michael's Hospital, Bristol, BS2 8EG, UK
| | - Ingrid Bader
- Department of Clinical Genetics, University Children's Hospital, Paracelsus Medical University, Salzburg, A-5020, Austria
| | - Johannes A Mayr
- Department of Pediatrics, Salzburger Landeskliniken and Paracelsus Medical University, Salzburg, A-5020, Austria
| | - Saskia B Wortmann
- Department of Pediatrics, Salzburger Landeskliniken and Paracelsus Medical University, Salzburg, A-5020, Austria.,Institute of Human Genetics, Technische Universität München, Munich, 81675, Germany.,Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, 85764, Germany
| | - Kathy J Jakielski
- Communication Sciences and Disorders, Augustana College, Rock Island, IL 61201, USA
| | - Edythe A Strand
- Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
| | - Katja Kloth
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Tatjana Bierhals
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | | | - John D Roberts
- National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
| | - Robert M Petrovich
- National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
| | | | | | - Stefan Lelieveld
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands
| | - Rolph Pfundt
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands
| | - Sandra Jansen
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.,Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands
| | - Pelagia Deriziotis
- Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, 6500AH, The Netherlands
| | - Laurence Faivre
- Equipe Génétique des Anomalies du Développement, Université de Bourgogne-Franche Comté, Dijon, 21070, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon et Université de Bourgogne, Dijon, 21079, France
| | - Julien Thevenon
- Equipe Génétique des Anomalies du Développement, Université de Bourgogne-Franche Comté, Dijon, 21070, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon et Université de Bourgogne, Dijon, 21079, France
| | - Mirna Assoum
- Equipe Génétique des Anomalies du Développement, Université de Bourgogne-Franche Comté, Dijon, 21070, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon et Université de Bourgogne, Dijon, 21079, France
| | | | - Tjitske Kleefstra
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.,Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands
| | - Han G Brunner
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.,Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands.,Department of Clinical Genetics and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, 6202AZ, The Netherlands
| | - Paul A Wade
- National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
| | - Simon E Fisher
- Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, 6500AH, The Netherlands. .,Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands.
| | - Philippe M Campeau
- CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada. .,Sainte-Justine Hospital, University of Montreal, Montreal, QC H3T 1C5, Canada.
| |
Collapse
|
14
|
Blok LS, Rousseau J, Twist J, Ehresmann S, Takaku M, Venselaar H, Rodan LH, Nowak CB, Douglas J, Swoboda KJ, Steeves MA, Sahai I, Stumpel CTRM, Stegmann APA, Wheeler P, Willing M, Fiala E, Kochhar A, Gibson WT, Cohen ASA, Agbahovbe R, Innes AM, Au PYB, Rankin J, Anderson IJ, Skinner SA, Louie RJ, Warren HE, Afenjar A, Keren B, Nava C, Buratti J, Isapof A, Rodriguez D, Lewandowski R, Propst J, van Essen T, Choi M, Lee S, Chae JH, Price S, Schnur RE, Douglas G, Wentzensen IM, Zweier C, Reis A, Bialer MG, Moore C, Koopmans M, Brilstra EH, Monroe GR, van Gassen KLI, van Binsbergen E, Newbury-Ecob R, Bownass L, Bader I, Mayr JA, Wortmann SB, Jakielski KJ, Strand EA, Kloth K, Bierhals T, Roberts JD, Petrovich RM, Machida S, Kurumizaka H, Lelieveld S, Pfundt R, Jansen S, Deriziotis P, Faivre L, Thevenon J, Assoum M, Shriberg L, Kleefstra T, Brunner HG, Wade PA, Fisher SE, Campeau PM. Author Correction: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language. Nat Commun 2019; 10:883. [PMID: 30770872 PMCID: PMC6377600 DOI: 10.1038/s41467-019-08800-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Affiliation(s)
- Lot Snijders Blok
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.,Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, 6500AH, The Netherlands.,Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands
| | - Justine Rousseau
- CHU Sainte-Justine Research Center, Montreal, QC, H3T 1C5, Canada
| | - Joanna Twist
- National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Sophie Ehresmann
- CHU Sainte-Justine Research Center, Montreal, QC, H3T 1C5, Canada
| | - Motoki Takaku
- National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Hanka Venselaar
- Centre for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands
| | - Lance H Rodan
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, 02115, USA
| | - Catherine B Nowak
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, 02115, USA
| | - Jessica Douglas
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, 02115, USA
| | - Kathryn J Swoboda
- Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA
| | - Marcie A Steeves
- Department of Medical Genetics, Massachusetts General Hospital, Boston, MA, 02114, USA
| | - Inderneel Sahai
- Department of Medical Genetics, Massachusetts General Hospital, Boston, MA, 02114, USA
| | - Connie T R M Stumpel
- Department of Clinical Genetics and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, 6202AZ, The Netherlands
| | - Alexander P A Stegmann
- Department of Clinical Genetics and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, 6202AZ, The Netherlands
| | | | - Marcia Willing
- Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Elise Fiala
- Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | | | - William T Gibson
- British Columbia Children's Hospital Research Institute, Vancouver, BC, V5Z 4H4, Canada.,Department of Medical Genetics, University of British Columbia, Vancouver, BC, V6H 3N1, Canada
| | - Ana S A Cohen
- British Columbia Children's Hospital Research Institute, Vancouver, BC, V5Z 4H4, Canada.,Department of Medical Genetics, University of British Columbia, Vancouver, BC, V6H 3N1, Canada
| | - Ruky Agbahovbe
- British Columbia Children's Hospital Research Institute, Vancouver, BC, V5Z 4H4, Canada.,Department of Medical Genetics, University of British Columbia, Vancouver, BC, V6H 3N1, Canada
| | - A Micheil Innes
- Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 4N1, Canada
| | - P Y Billie Au
- Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 4N1, Canada
| | - Julia Rankin
- Department of Clinical Genetics, Royal Devon and Exeter NHS Foundation Trust (Heavitree), Exeter, EX2 5DW, UK
| | - Ilse J Anderson
- Division of Genetics, Department of Medicine, University of Tennessee Medical Center, Knoxville, TN, 37920, USA
| | | | | | | | - Alexandra Afenjar
- GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris ; Department of Medical Genetics and Centre de Référence Malformations et maladies congénitales du cervelet et déficiences intellectuelles de causes rares, Armand Trousseau Hospital, GHUEP, AP-HP, Paris, 75012, France
| | - Boris Keren
- AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, 75013, France.,Groupe de Recherche Clinique (GRC) 'déficience intellectuelle et autisme' UPMC, Paris, 75005, France
| | - Caroline Nava
- AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, 75013, France.,Groupe de Recherche Clinique (GRC) 'déficience intellectuelle et autisme' UPMC, Paris, 75005, France.,INSERM, U 1127, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, 75013, Paris, France
| | - Julien Buratti
- AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, 75013, France
| | - Arnaud Isapof
- GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris 06; Department Child Neurology and Reference Center for Neuromuscular Diseases "Nord/Est/Ile-de-France", FILNEMUS, Armand Trousseau Hospital, GHUEP, AP-HP, Paris, 75012, France
| | - Diana Rodriguez
- GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris 06; Department of Child Neurology and National Reference Center for Neurogenetic Disorders, Armand Trousseau Hospital, GHUEP, AP-HP, INSERM U1141, 75012, Paris, France
| | - Raymond Lewandowski
- Clinical Genetics Division, Virginia Commonwealth University Health System, Richmond, VA, 23298, USA
| | - Jennifer Propst
- Clinical Genetics Division, Virginia Commonwealth University Health System, Richmond, VA, 23298, USA
| | - Ton van Essen
- Clinical Genetics Department, University Medical Center Groningen, Groningen, 9700RB, The Netherlands
| | - Murim Choi
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 08826, Republic of Korea
| | - Sangmoon Lee
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 08826, Republic of Korea
| | - Jong H Chae
- Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children's Hospital, Seoul, 08826, Republic of Korea
| | - Susan Price
- Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7HE, UK
| | | | | | | | - Christiane Zweier
- Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany
| | - André Reis
- Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany
| | - Martin G Bialer
- Northwell Health, Division of Medical Genetics and Genomics, Great Neck NY, 11021, USA
| | - Christine Moore
- Northwell Health, Division of Medical Genetics and Genomics, Great Neck NY, 11021, USA
| | - Marije Koopmans
- Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, 3508AB, The Netherlands
| | - Eva H Brilstra
- Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, 3508AB, The Netherlands
| | - Glen R Monroe
- Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, 3508AB, The Netherlands
| | - Koen L I van Gassen
- Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, 3508AB, The Netherlands
| | - Ellen van Binsbergen
- Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, 3508AB, The Netherlands
| | - Ruth Newbury-Ecob
- University Hospitals Bristol, Department of Clinical Genetics, St Michael's Hospital, Bristol, BS2 8EG, UK
| | - Lucy Bownass
- University Hospitals Bristol, Department of Clinical Genetics, St Michael's Hospital, Bristol, BS2 8EG, UK
| | - Ingrid Bader
- Department of Clinical Genetics, University Children's Hospital, Paracelsus Medical University, Salzburg, A-5020, Austria
| | - Johannes A Mayr
- Department of Pediatrics, Salzburger Landeskliniken and Paracelsus Medical University, Salzburg, A-5020, Austria
| | - Saskia B Wortmann
- Department of Pediatrics, Salzburger Landeskliniken and Paracelsus Medical University, Salzburg, A-5020, Austria.,Institute of Human Genetics, Technische Universität München, Munich, 81675, Germany.,Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, 85764, Germany
| | - Kathy J Jakielski
- Communication Sciences and Disorders, Augustana College, Rock Island, IL, 61201, USA
| | - Edythe A Strand
- Department of Neurology, Mayo Clinic, Rochester, MN, 55905, USA
| | - Katja Kloth
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Tatjana Bierhals
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | | | - John D Roberts
- National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Robert M Petrovich
- National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | | | | | - Stefan Lelieveld
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands
| | - Rolph Pfundt
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands
| | - Sandra Jansen
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.,Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands
| | - Pelagia Deriziotis
- Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, 6500AH, The Netherlands
| | - Laurence Faivre
- Equipe Génétique des Anomalies du Développement, Université de Bourgogne- Franche Comté, Dijon, 21070, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon et Université de Bourgogne, Dijon, 21079, France
| | - Julien Thevenon
- Equipe Génétique des Anomalies du Développement, Université de Bourgogne- Franche Comté, Dijon, 21070, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon et Université de Bourgogne, Dijon, 21079, France
| | - Mirna Assoum
- Equipe Génétique des Anomalies du Développement, Université de Bourgogne- Franche Comté, Dijon, 21070, France.,Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon et Université de Bourgogne, Dijon, 21079, France
| | | | - Tjitske Kleefstra
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.,Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands
| | - Han G Brunner
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.,Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands.,Department of Clinical Genetics and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, 6202AZ, The Netherlands
| | - Paul A Wade
- National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Simon E Fisher
- Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, 6500AH, The Netherlands. .,Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands.
| | - Philippe M Campeau
- CHU Sainte-Justine Research Center, Montreal, QC, H3T 1C5, Canada. .,Sainte-Justine Hospital, University of Montreal, Montreal, QC, H3T 1C5, Canada.
| |
Collapse
|
15
|
Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 2018; 18:569-575.e1. [PMID: 30122201 DOI: 10.1016/j.clml.2018.05.023] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Revised: 05/23/2018] [Accepted: 05/30/2018] [Indexed: 12/17/2022]
Abstract
BACKGROUND The proteasome inhibitor bortezomib has demonstrated marked preclinical activity when combined with the histone deacetylase inhibitor vorinostat in leukemia, multiple myeloma, and mantle cell lymphoma (MCL) cells. The present study evaluated the efficacy and safety of the combination in patients with relapsed or refractory MCL and diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS The present multicenter, nonrandomized phase II trial used a Simon 2-stage design with 3 cohorts: cohort A, MCL with no previous bortezomib (including untreated MCL); cohort B, MCL with previous bortezomib; and cohort C, relapsed or refractory DLBCL with no previous bortezomib. Vorinostat (400 mg) was administered orally on days 1 to 5 and 8 to 12 before bortezomib (1.3 mg/m2), which was administered intravenously on days 1, 4, 8, and 11 of each 21-day cycle. RESULTS For the 65 treated patients (22 in cohort A, 4 in cohort B, and 39 in cohort C), the overall response rate was 31.8%, 0%, and 7.7%, respectively. The median progression-free survival was 7.6 months for cohort A and 1.8 months for cohort C. In cohort A, 7 patients had a partial response (PRs), 5 had stable disease (SD), 7 had progressive disease (PD), 1 was not assessed, and 2 were not evaluable. In cohort B, 2 had SD and 2 had PD. In cohort C, 3 had a PR, 8 had SD, 23 had PD, and 5 were not assessed. Baseline NF-κB activation, measured as nuclear RelA by immunohistochemistry, did not correlate with clinical response. CONCLUSION The combination of bortezomib and vorinostat is safe and has modest activity in MCL and limited activity in DLBCL.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Bortezomib/administration & dosage
- Drug Resistance, Neoplasm/drug effects
- Female
- Follow-Up Studies
- Humans
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/pathology
- Lymphoma, Mantle-Cell/drug therapy
- Lymphoma, Mantle-Cell/pathology
- Male
- Middle Aged
- Neoplasm Recurrence, Local/drug therapy
- Neoplasm Recurrence, Local/pathology
- Prognosis
- Prospective Studies
- Salvage Therapy
- Survival Rate
- Vorinostat/administration & dosage
Collapse
Affiliation(s)
- Victor Yazbeck
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
| | - Danielle Shafer
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
| | - Edward B Perkins
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA
| | - Domenico Coppola
- Department of Pathology, H. Lee Moffitt Cancer Center, Tampa, FL
| | - Lubomir Sokol
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
| | - Kristy L Richards
- Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - Thomas Shea
- Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - Jia Ruan
- Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY
| | - Samir Parekh
- Department of Oncology, Montefiore Medical Center, Bronx, NY
| | - Roger Strair
- Cancer Institute of New Jersey, New Brunswick, NJ
| | | | | | - Maciej Kmieciak
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
| | - Prithviraj Bose
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA
| | - Amy Kimball
- Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD
| | - Ashraf Z Badros
- Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD
| | - Rachid Baz
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
| | - Hui-Yi Lin
- Department of Biostatistics and Biomedical Informatics, H. Lee Moffitt Cancer Center, Tampa, FL
| | - Xiuhua Zhao
- Department of Biostatistics and Biomedical Informatics, H. Lee Moffitt Cancer Center, Tampa, FL
| | - Richard R Reich
- Department of Biostatistics and Biomedical Informatics, H. Lee Moffitt Cancer Center, Tampa, FL
| | - Mary Beth Tombes
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
| | - Ellen Shrader
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
| | - Heidi Sankala
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
| | - John D Roberts
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA
| | - Daniel Sullivan
- Department of Blood and Marrow Transplantation and Cellular Immunology, H. Lee Moffitt Cancer Center, Tampa, FL
| | - Steven Grant
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA; Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA; Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA; Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA
| | - Beata Holkova
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA.
| |
Collapse
|
16
|
Abstract
Introduction: Legal access to marijuana, most frequently as “medical marijuana,” is becoming more common in the United States, but most states do not specify sickle cell disease as a qualifying condition. We were aware that some of our patients living with sickle cell disease used illicit marijuana, and we sought more information about this. Materials and Methods: We practice at an urban, academic medical center and provide primary, secondary, and tertiary care for ∼130 adults living with sickle cell disease. We surveyed our patients with a brief, anonymous, paper-and-pen instrument. We reviewed institutional records for clinically driven urine drug testing. We tracked patient requests for certification for medical marijuana. Results: Among 58 patients surveyed, 42% reported marijuana use within the past 2 years. Among users, most endorsed five medicinal indications; a minority reported recreational use. Among 57 patients who had at least one urine drug test, 18% tested positive for cannabinoids only, 12% tested positive for cocaine and/or phencyclidine only, and 5% tested positive for both cannabinoids and cocaine/phencyclidine. Subsequent to these studies, sickle cell disease became a qualifying condition for medical marijuana in our state. In the interval ∼1.5 years, 44 patients have requested certification. Conclusion: Our findings and those of others create a rationale for research into the possible therapeutic effects of marijuana or cannabinoids, the presumed active constituents of marijuana, in sickle cell disease. Explicit inclusion of sickle cell disease as a qualifying condition for medical marijuana might reduce illicit marijuana use and related risks and costs to both persons living with sickle cell disease and society.
Collapse
Affiliation(s)
- John D Roberts
- Yale Cancer Center, Yale University, New Haven, Connecticut
| | - Jonathan Spodick
- Department of Social Work, Yale New Haven Hospital, New Haven, Connecticut
| | - Joanna Cole
- Department of Community Health Outpatient Practice, Yale New Haven Hospital, New Haven, Connecticut
| | - Janis Bozzo
- Department of Information Technology Services Analytics Strategy, Yale New Haven Health, New Haven, Connecticut
| | - Susanna Curtis
- Yale Cancer Center, Yale University, New Haven, Connecticut
| | - Ariadna Forray
- Department of Psychiatry, Yale University, New Haven, Connecticut
| |
Collapse
|
17
|
Takaku M, Grimm SA, Roberts JD, Chrysovergis K, Myers P, Perou CM, Wade PA. Abstract 5418: GATA3 zinc-finger mutation induces transcriptional reprogramming in breast cancer through gain and loss of function. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Recent large-scale breast cancer genomic profiling identified frequent mutations in a pioneer transcription factor, GATA3. The expression of GATA3 is a prominent marker of luminal breast tumors, and loss of GATA3 expression is associated with aggressive tumor phenotypes. In addition, GATA3 mutations are frequently found in these luminal tumors. However, the clinical and molecular outcomes of GATA3 mutations are poorly understood. Our novel classification scheme of GATA3 mutations defines distinct clinical features of breast tumors with mutations in the second GATA3 zinc-finger (ZnFn2): frequent observation in luminal B subtype and worse prognosis than other GATA3 mutant cases. To dissect the molecular impacts of these ZnFn2 mutations, we generated a GATA3 mutant breast cancer cell clone by CRISPR-Cas9 gene editing. An engineered ZnFn2 mutant cell line manifested increased tumor growth as xenografts and more aggressive phenotypes in vitro. The ZnFn2 mutation led to loss of GATA3 binding and decreased expression at a subset of genes, including progesterone receptor (PR). The mutant cells also exhibited gain of GATA3 binding at other loci, correlated with increased expression of mesenchymal marker genes. Decreased expression of PR and impaired response to progesterone were crucial for cancer-promoting functions in GATA3 ZnFn2 mutant cells. Downregulation of PR and its downstream genes was also observed in the clinical gene expression data. These results illuminate tumor-promoting functions of GATA3 ZnFn2 mutations in breast cancer.
Citation Format: Motoki Takaku, Sara A. Grimm, John D. Roberts, Kaliopi Chrysovergis, Page Myers, Charles M. Perou, Paul A. Wade. GATA3 zinc-finger mutation induces transcriptional reprogramming in breast cancer through gain and loss of function [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5418.
Collapse
Affiliation(s)
- Motoki Takaku
- 1National Institute of Environmental Health Sciences, Research Triangle Park, NC
| | - Sara A. Grimm
- 1National Institute of Environmental Health Sciences, Research Triangle Park, NC
| | - John D. Roberts
- 1National Institute of Environmental Health Sciences, Research Triangle Park, NC
| | - Kaliopi Chrysovergis
- 1National Institute of Environmental Health Sciences, Research Triangle Park, NC
| | - Page Myers
- 1National Institute of Environmental Health Sciences, Research Triangle Park, NC
| | - Charles M. Perou
- 2Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
| | - Paul A. Wade
- 1National Institute of Environmental Health Sciences, Research Triangle Park, NC
| |
Collapse
|
18
|
Hafla E, Johnson E, Johnson CN, Preston L, Aldridge D, Roberts JD. Modeling underwater noise propagation from marine hydrokinetic power devices through a time-domain, velocity-pressure solution. J Acoust Soc Am 2018; 143:3242. [PMID: 29960489 DOI: 10.1121/1.5039839] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Marine hydrokinetic (MHK) devices generate electricity from the motion of tidal and ocean currents, as well as ocean waves, to provide an additional source of renewable energy available to the United States. These devices are a source of anthropogenic noise in the marine ecosystem and must meet regulatory guidelines that mandate a maximum amount of noise that may be generated. In the absence of measured levels from in situ deployments, a model for predicting the propagation of sound from an array of MHK sources in a real environment is essential. A set of coupled, linearized velocity-pressure equations in the time-domain are derived and presented in this paper, which are an alternative solution to the Helmholtz and wave equation methods traditionally employed. Discretizing these equations on a three-dimensional (3D), finite-difference grid ultimately permits a finite number of complex sources and spatially varying sound speeds, bathymetry, and bed composition. The solution to this system of equations has been parallelized in an acoustic-wave propagation package developed at Sandia National Labs, called Paracousti. This work presents the broadband sound pressure levels from a single source in two-dimensional (2D) ideal and Pekeris wave-guides and in a 3D domain with a sloping boundary. The paper concludes with demonstration of Paracousti for an array of MHK sources in a simple wave-guide.
Collapse
Affiliation(s)
- E Hafla
- Department of Mechanical and Industrial Engineering, Montana State University, Bozeman, Montana, 59718, USA
| | - E Johnson
- Department of Mechanical and Industrial Engineering, Montana State University, Bozeman, Montana, 59718, USA
| | - C N Johnson
- DNV GL Energy and Sustainability, 1501 4th Avenue Suite 900, Seattle, Washington 98101, USA
| | - L Preston
- Sandia National Laboratories, 1515 Eubank Southeast, Albuquerque, New Mexico 87123, USA
| | - D Aldridge
- Sandia National Laboratories, 1515 Eubank Southeast, Albuquerque, New Mexico 87123, USA
| | - J D Roberts
- Sandia National Laboratories, 1515 Eubank Southeast, Albuquerque, New Mexico 87123, USA
| |
Collapse
|
19
|
Takaku M, Grimm SA, Roberts JD, Chrysovergis K, Bennett BD, Myers P, Perera L, Tucker CJ, Perou CM, Wade PA. GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 2018. [PMID: 29535312 PMCID: PMC5849768 DOI: 10.1038/s41467-018-03478-4] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
GATA3 is frequently mutated in breast cancer; these mutations are widely presumed to be loss-of function despite a dearth of information regarding their effect on disease course or their mechanistic impact on the breast cancer transcriptional network. Here, we address molecular and clinical features associated with GATA3 mutations. A novel classification scheme defines distinct clinical features for patients bearing breast tumors with mutations in the second GATA3 zinc-finger (ZnFn2). An engineered ZnFn2 mutant cell line by CRISPR–Cas9 reveals that mutation of one allele of the GATA3 second zinc finger (ZnFn2) leads to loss of binding and decreased expression at a subset of genes, including Progesterone Receptor. At other loci, associated with epithelial to mesenchymal transition, gain of binding correlates with increased gene expression. These results demonstrate that not all GATA3 mutations are equivalent and that ZnFn2 mutations impact breast cancer through gain and loss-of function. In breast cancer GATA3 is known to be frequently mutated, but the function of these mutations is unclear. Here, the authors utilise CRISPR-Cas9 to model frame-shift mutations in zinc finger 2 of GATA3, highlighting that GATA3 mutation can have gain- or loss-of function effects in breast cancer.
Collapse
Affiliation(s)
- Motoki Takaku
- Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, 27709, USA
| | - Sara A Grimm
- Integrative Bioinformatics, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, 27709, USA
| | - John D Roberts
- Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, 27709, USA
| | - Kaliopi Chrysovergis
- Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, 27709, USA
| | - Brian D Bennett
- Integrative Bioinformatics, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, 27709, USA
| | - Page Myers
- Comparative Medicine Branch, National Institute of Environmental Health Sciences, Research Triangle Park, 27709, Durham, NC, USA
| | - Lalith Perera
- Laboratory of Genome Integrity and Structural Biology, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, 27709, USA
| | - Charles J Tucker
- Fluorescence Microscopy and Imaging Center, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, 27709, USA
| | - Charles M Perou
- Lineberger Comprehensive Cancer Center and Department of Genetics, University of North Carolina, Chapel Hill, NC, 27599, USA
| | - Paul A Wade
- Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, 27709, USA.
| |
Collapse
|
20
|
Qin Y, Roberts JD, Grimm SA, Lih FB, Deterding LJ, Li R, Chrysovergis K, Wade PA. An obesity-associated gut microbiome reprograms the intestinal epigenome and leads to altered colonic gene expression. Genome Biol 2018; 19:7. [PMID: 29361968 PMCID: PMC5782396 DOI: 10.1186/s13059-018-1389-1] [Citation(s) in RCA: 82] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Accepted: 01/09/2018] [Indexed: 02/08/2023] Open
Abstract
Background The gut microbiome, a key constituent of the colonic environment, has been implicated as an important modulator of human health. The eukaryotic epigenome is postulated to respond to environmental stimuli through alterations in chromatin features and, ultimately, gene expression. How the host mediates epigenomic responses to gut microbiota is an emerging area of interest. Here, we profile the gut microbiome and chromatin characteristics in colon epithelium from mice fed either an obesogenic or control diet, followed by an analysis of the resultant changes in gene expression. Results The obesogenic diet shapes the microbiome prior to the development of obesity, leading to altered bacterial metabolite production which predisposes the host to obesity. This microbiota–diet interaction leads to changes in histone modification at active enhancers that are enriched for binding sites for signal responsive transcription factors. These alterations of histone methylation and acetylation are associated with signaling pathways integral to the development of colon cancer. The transplantation of obesogenic diet-conditioned microbiota into germ free mice, combined with an obesogenic diet, recapitulates the features of the long-term diet regimen. The diet/microbiome-dependent changes are reflected in both the composition of the recipient animals’ microbiome as well as in the set of transcription factor motifs identified at diet-influenced enhancers. Conclusions These findings suggest that the gut microbiome, under specific dietary exposures, stimulates a reprogramming of the enhancer landscape in the colon, with downstream effects on transcription factors. These chromatin changes may be associated with those seen during colon cancer development. Electronic supplementary material The online version of this article (10.1186/s13059-018-1389-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yufeng Qin
- Eukaryotic Transcriptional Regulation Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - John D Roberts
- Eukaryotic Transcriptional Regulation Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Sara A Grimm
- Integrative Bioinformatics Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Fred B Lih
- Mass Spectrometry Research & Support Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Leesa J Deterding
- Mass Spectrometry Research & Support Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Ruifang Li
- Eukaryotic Transcriptional Regulation Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Kaliopi Chrysovergis
- Eukaryotic Transcriptional Regulation Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA
| | - Paul A Wade
- Eukaryotic Transcriptional Regulation Group, Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709, USA.
| |
Collapse
|
21
|
Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P. Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget 2018; 7:42625-42638. [PMID: 27213589 PMCID: PMC5173162 DOI: 10.18632/oncotarget.9434] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Accepted: 04/16/2016] [Indexed: 01/16/2023] Open
Abstract
Purpose To determine if combination treatment with pemetrexed and sorafenib is safe and tolerable in patients with advanced solid tumors. Results Thirty-seven patients were enrolled and 36 patients were treated (24 in cohort A; 12 in cohort B). The cohort A dose schedule resulted in problematic cumulative toxicity, while the cohort B dose schedule was found to be more tolerable. The maximum tolerated dose (MTD) was pemetrexed 750 mg/m2 every 14 days with oral sorafenib 400 mg given twice daily on days 1–5. Because dosing delays and modifications were associated with the MTD, the recommended phase II dose was declared to be pemetrexed 500 mg/m2 every 14 days with oral sorafenib 400 mg given twice daily on days 1–5. Thirty-three patients were evaluated for antitumor activity. One complete response and 4 partial responses were observed (15% overall response rate). Stable disease was seen in 15 patients (45%). Four patients had a continued response at 6 months, including 2 of 5 patients with triple-negative breast cancer. Experimental Design A phase I trial employing a standard 3 + 3 design was conducted in patients with advanced solid tumors. Cohort A involved a novel dose escalation schema exploring doses of pemetrexed every 14 days with continuous sorafenib. Cohort B involved a modified schedule of sorafenib dosing on days 1–5 of each 14-day pemetrexed cycle. Radiographic assessments were conducted every 8 weeks. Conclusions Pemetrexed and intermittent sorafenib therapy is a safe and tolerable combination for patients, with promising activity seen in patients with breast cancer.
Collapse
Affiliation(s)
- Andrew Poklepovic
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.,Departments of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Sarah Gordon
- Departments of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Danielle A Shafer
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.,Departments of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
| | - John D Roberts
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.,Departments of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.,Current address: Department of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA
| | - Prithviraj Bose
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.,Departments of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.,Current address: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Charles E Geyer
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.,Departments of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
| | - William P McGuire
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.,Departments of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Mary Beth Tombes
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Ellen Shrader
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Katie Strickler
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Maria Quigley
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Wen Wan
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.,Departments of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Maciej Kmieciak
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
| | - H Davis Massey
- Departments of Pathology, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Laurence Booth
- Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Richard G Moran
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.,Departments of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Paul Dent
- Departments of Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.,Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia, USA
| |
Collapse
|
22
|
Shimbo T, Dunnick JK, Brix A, Mav D, Shah R, Roberts JD, Wade PA. DNA Methylation Changes in Tbx3 in a Mouse Model Exposed to Polybrominated Diphenyl Ethers. Int J Toxicol 2017; 36:229-238. [PMID: 28466692 DOI: 10.1177/1091581817706676] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
DE-71, a commercial mixture of polybrominated diphenyl ethers widely used in flame retardants, is a pervasive environmental contaminant due to its continuing release from waste material and its long half-life in humans. Although the genotoxic potential of DE-71 appears to be low based on bacterial mutagenicity, it remains a public health concern due to its reported involvement in tumor development. Molecular mechanisms by which DE-71 influences tumor incidence or progression remain understudied. We used liver carcinoma tissue from mice exposed to DE-71 to test the hypothesis that epigenetic alterations consistent with tumor development, specifically DNA methylation, result from long-term DE-71 exposure. We profiled DNA methylation status using the methylated-CpG island recovery assay coupled with microarray analysis of hepatocellular carcinoma DNA from animals exposed to DE-71. DE-71 exposure had little impact on global DNA methylation. However, we detected gene body-specific hypomethylation within the Tbx3 locus, a transcription factor important in liver tumorigenesis and in embryonic and cancer stem cell proliferation. This nonpromoter hypomethylation was accompanied by upregulation of Tbx3 mRNA and protein and by alterations in downstream cell cycle-associated marker expression. Thus, exposure to DE-71 may facilitate tumor development by inducing epigenetic programs that favor expansion of progenitor cell populations.
Collapse
Affiliation(s)
- Takashi Shimbo
- 1 Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
| | - June K Dunnick
- 2 National Toxicology Program, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
| | - Amy Brix
- 2 National Toxicology Program, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA.,3 EPL Inc, Research Triangle Park, NC, USA
| | - Deepak Mav
- 4 Sciome LLC, Research Triangle Park, NC, USA
| | - Ruchir Shah
- 4 Sciome LLC, Research Triangle Park, NC, USA
| | - John D Roberts
- 1 Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
| | - Paul A Wade
- 1 Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
| |
Collapse
|
23
|
Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, Shea TC, Grant S. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 2017; 58:1349-1357. [PMID: 28103725 DOI: 10.1080/10428194.2016.1276287] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
A phase 1 study was conducted to determine the dose-limiting toxicities and maximum-tolerated dose (MTD) for bortezomib followed by romidepsin on days 1, 8, and 15 in patients with relapsed/refractory CLL/SLL or B- or T-cell lymphoma. Eighteen treated patients were evaluable for response. The MTD was 1.3 mg/m2 bortezomib and 10 mg/m2 romidepsin; median treatment duration was 3 cycles at this dose. The dose-limiting toxicities were grade 3 fatigue, vomiting, and chills. Two patients had partial responses, one lasting >2 years, 8 had stable disease, and 8 had progressive disease. The median duration of stable disease was 3.5 cycles. Correlative studies examining expression of NF-кB, XIAP, Bcl-xL, and Bim yielded variable results. The safety profile was consistent with that reported for single-agent bortezomib and romidepsin. This regimen has modest activity in heavily pretreated patients with relapsed/refractory CLL or B- or T-cell lymphoma. NCT00963274.
Collapse
Affiliation(s)
- Beata Holkova
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.,b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA
| | - Victor Yazbeck
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.,b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA
| | - Maciej Kmieciak
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA
| | - Prithviraj Bose
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA
| | - Shuo Ma
- c Division of Hematology and Oncology , Robert H. Lurie Comprehensive Cancer Center, Northwestern University , Chicago , IL , USA
| | - Amy Kimball
- d Marlene and Stewart Greenebaum Cancer Center, University of Maryland , Baltimore , MD , USA
| | - Mary Beth Tombes
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA
| | - Ellen Shrader
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA
| | - Wen Wan
- e Department of Statistics , Virginia Commonwealth University , Richmond , VA , USA
| | - Caryn Weir-Wiggins
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA
| | - Amanda Singh
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA
| | - Kevin T Hogan
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA
| | - Sarah Conine
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA
| | - Heidi Sankala
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA
| | - John D Roberts
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA
| | - Thomas C Shea
- f Department of Hematology/Oncology , Lineberger Comprehensive Cancer Center, University of North Carolina , Chapel Hill , NC , USA
| | - Steven Grant
- a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.,b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA.,g Department of Microbiology and Immunology , Virginia Commonwealth University , Richmond , VA , USA.,h Department of Biochemistry and Molecular Biology , Virginia Commonwealth University , Richmond , VA , USA.,i The Institute for Molecular Medicine, Virginia Commonwealth University , Richmond , VA , USA
| |
Collapse
|
24
|
Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 2017; 317:48-58. [PMID: 28030702 PMCID: PMC5321662 DOI: 10.1001/jama.2016.19425] [Citation(s) in RCA: 201] [Impact Index Per Article: 28.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain. OBJECTIVE To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks. DESIGN, SETTING, PARTICIPANTS Randomized, open-label clinical trial conducted at 269 academic and community sites in the United States. Patients (n = 1822) with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma who had at least 1 site of bone involvement were enrolled between May 2009 and April 2012; follow-up concluded in April 2014. INTERVENTIONS Patients were randomized to receive zoledronic acid administered intravenously every 4 weeks (n = 911) vs every 12 weeks (n = 911) for 2 years. MAIN OUTCOMES AND MEASURES The primary end point was the proportion of patients having at least 1 skeletal-related event (defined as clinical fracture, spinal cord compression, radiation to bone, or surgery involving bone) within 2 years after randomization and a between-group absolute difference of 7% as the noninferiority margin. Secondary end points included the proportion of patients with at least 1 skeletal-related event by disease type, pain as assessed by the Brief Pain Inventory (range, 0-10; higher scores indicate worse pain), Eastern Cooperative Oncology Group performance status (range, 0-4; higher scores indicate worse disability), incidence of osteonecrosis of the jaw, kidney dysfunction, skeletal morbidity rate (mean number of skeletal-related events per year), and, in a subset of 553 patients, suppression of bone turnover (assessed by C-terminal telopeptide levels). RESULTS Among 1822 patients who were randomized (median age, 65 years; 980 [53.8%] women; 855 with breast cancer, 689 with prostate cancer, and 278 with multiple myeloma), 795 completed the study at 2 years. A total of 260 patients (29.5%) in the zoledronic acid every 4-week dosing group and 253 patients (28.6%) in the every 12-week dosing group experienced at least 1 skeletal-related event within 2 years of randomization (risk difference of -0.3% [1-sided 95% CI, -4% to ∞]; P < .001 for noninferiority). The proportions of skeletal-related events did not differ significantly between the every 4-week dosing group vs the every 12-week dosing group for patients with breast cancer, prostate cancer, or multiple myeloma. Pain scores, performance status scores, incidence of jaw osteonecrosis, and kidney dysfunction did not differ significantly between the treatment groups. Skeletal morbidity rates were numerically identical in both groups, but bone turnover was greater (C-terminal telopeptide levels were higher) among patients who received zoledronic acid every 12 weeks. CONCLUSIONS AND RELEVANCE Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, the use of zoledronic acid every 12 weeks compared with the standard dosing interval of every 4 weeks did not result in an increased risk of skeletal events over 2 years. This longer interval may be an acceptable treatment option. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00869206.
Collapse
Affiliation(s)
| | - Jared C Foster
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota
| | | | - John D Roberts
- VCU Massey Cancer Center, Richmond, Virginia5Now with Yale University, New Haven, Connecticut
| | - Drew K Seisler
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota
| | - Paul J Novotny
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota
| | - Rui Qin
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota6Now with Regeneron Pharmaceuticals, Basking Ridge, New Jersey
| | - Ronald S Go
- Gundersen Health System, La Crosse, Wisconsin8Now with Mayo Clinic, Rochester, Minnesota
| | - Stephen S Grubbs
- Helen F. Graham Cancer Center & Research Institute, Newark, Delaware9Now with American Society of Clinical Oncology, Alexandria, Virginia
| | | | | | | | - Ann O'Mara
- Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland
| | | | | |
Collapse
|
25
|
|
26
|
Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. A phase I study of indoximod in patients with advanced malignancies. Oncotarget 2016; 7:22928-38. [PMID: 27008709 PMCID: PMC5008412 DOI: 10.18632/oncotarget.8216] [Citation(s) in RCA: 105] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2016] [Accepted: 03/10/2016] [Indexed: 01/17/2023] Open
Abstract
PURPOSE Indoximod is an oral inhibitor of the indoleamine 2,3-dioxygenase pathway, which causes tumor-mediated immunosuppression. Primary endpoints were maximum tolerated dose (MTD) and toxicity for indoximod in patients with advanced solid tumors. Secondary endpoints included response rates, pharmacokinetics, and immune correlates. EXPERIMENTAL DESIGN Our 3+3 phase I trial comprised 10 dose levels (200, 300, 400, 600, and 800 mg once/day; 600, 800, 1200, 1600, and 2000 mg twice/day). Inclusion criteria were measurable metastatic solid malignancy, age ≥18 years, and adequate organ/marrow function. Exclusion criteria were chemotherapy ≤ 3 weeks prior, untreated brain metastases, autoimmune disease, or malabsorption. RESULTS In 48 patients, MTD was not reached at 2000 mg twice/day. At 200 mg once/day, 3 patients previously treated with checkpoint inhibitors developed hypophysitis. Five patients showed stable disease >6 months. Indoximod plasma AUC and Cmax plateaued above 1200mg. Cmax (~12 μM at 2000 mg twice/day) occurred at 2.9 hours, and half-life was 10.5 hours. C reactive protein (CRP) levels increased across multiple dose levels. CONCLUSIONS Indoximod was safe at doses up to 2000 mg orally twice/day. Best response was stable disease >6 months in 5 patients. Induction of hypophysitis, increased tumor antigen autoantibodies and CRP levels were observed.
Collapse
Affiliation(s)
- Hatem H. Soliman
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Susan E. Minton
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Hyo Sook Han
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Roohi Ismail-Khan
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Anthony Neuger
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Fatema Khambati
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - David Noyes
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Richard Lush
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | | | - John D. Roberts
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
| | | | | | | | - Howard Streicher
- Cancer Therapeutics Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA
| | - Daniel M. Sullivan
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Scott J. Antonia
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| |
Collapse
|
27
|
Kim JW, Kang Y, Shin M, Deshpande HA, Hurwitz ME, Roberts JD, Cardinale JG, Narayana A, Kang I, Petrylak DP. Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.2_suppl.295] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
295 Background: The bone seeking calcium mimetic, Radium223 (Ra223), emits high energy alpha particle that cause irreparable double strand DNA breaks in osseous metastases. Ra223 improves survival in patients with bone-predominant metastatic castration resistant prostate cancer (mCRPC). The effect of Ra223 on the host immune system, and T cell immunity in particular, is unknown. Methods: Eligible patients include men with mCRPC, osseous metastases and a clinical indication for Ra223 were eligible. Blood samples were collected at the following time points: prior to the first, second, and fourth treatments (tx) and 4 weeks after the sixth dose. Peripheral blood mononuclear cells (PBMCs) were purified and stained with a cocktail of antibodies to surface and effector immune molecules. Some PBMCs were stimulated and stained for intracellular cytokines (IFN-g, TNF-a, IL-13, IL-17, and IL-21). Stained cells were analyzed by flow cytometry. Results: A total seven patients completed at least two sample collections. The median number of prior lines of therapy was three. Median age was 71 (55-79). Median PSA was 78 (2-351). Effector memory (EM) CD8+ T cells were divided into two subsets expressing high and low levels of the IL-7 receptor alpha chain (IL-7Ra) with distinct cellular characteristics including perforin expression. The frequency of IL-7Rahigh and low EM CD8+ T cells expressing programmed death protein 1 (PD-1) was decreased after Ra223 treatment (pre vs. post, median (%) ± interquartile range, 14.3 ± 12.9 vs. 7.2 ± 20.9, P = 0.03; 16.7 ± 28.8 vs. 14.1 ± 37.8, P = 0.015 by Wilcoxon matched-pairs signed rank test). A similar finding was observed in the frequency of memory CD4+ T cells expressing PD-1 after the treatment (median (%) ± interquartile range, 7.2 ± 7.7 vs. 3.9 ± 3.4, P= 0.03). Conclusions: In this preliminary cohort of patients, Ra223 tx was associated with decrease in PD-1 expression by effector T cells. Further investigations of an immune mechanism of Ra223 mediated antitumor activity are warranted.
Collapse
Affiliation(s)
- Joseph W. Kim
- Yale University Medical Center, Yale Cancer Center, New Haven, CT
| | | | | | | | | | | | - Joseph G. Cardinale
- Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT
| | | | | | | |
Collapse
|
28
|
Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak ARA, Roberts JD, Vokes EE, Cohen EEW. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol 2015; 27:318-23. [PMID: 26598548 DOI: 10.1093/annonc/mdv537] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2015] [Accepted: 10/26/2015] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Adenoid cystic carcinoma (ACC) is a subtype of malignant salivary gland tumors (MSGT), in which 90% of cases express cKIT. Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase families including cKIT. We conducted a phase II study to determine the antitumor activity of dasatinib in ACC and non-ACC MSGT. PATIENTS AND METHODS In a two-stage design, patients with progressive, recurrent/metastatic ACC (+cKIT) and non-ACC MSGT (separate cohort) were treated with dasatinib 70 mg p.o. b.i.d. Response was assessed every 8 weeks using RECIST. RESULTS Of 54 patients: 40 ACC, 14 non-ACC (1, ineligible excluded); M:F = 28 : 26, median age 56 years (range 20-82 years), ECOG performance status 0 : 1 : 2 = 24 : 28 : 2, prior radiation: 44, prior chemotherapy: 21. The most frequent adverse events (AEs) (as % of patients, worst grade 2 or higher) were: fatigue (28%), nausea (19%), headache (15%), lymphopenia (7%), dyspnea (11%), alanine aminotransferase increased (7%), anorexia (7%), vomiting (7%), alkaline phosphatase increased (6%), diarrhea (6%), neutropenia (6%), and noncardiac chest pain (6%). No grade 4 AE occurred, 15 patients experienced a grade 3 AE, primarily dyspnea (5) and fatigue (4), and cardiac toxicity (1 prolonged QTc). Among ACC patients, best response to dasatinib: 1 patient (2.5%) had partial response, 20 patients (50%) had stable disease (SD) (3-14 months), 12 patients (30%) had PD, 2 withdrew, 3 discontinued therapy due to AE, and 2 died before cycle 2. Median progression-free survival was 4.8 months. Median overall survival was 14.5 months. For 14 assessable non-ACC patients, none had objective response, triggering early stopping rule. Seven had SD (range 1-7 months), 4 PD, 2 discontinued therapy due to AE, and 1 died before cycle 2. CONCLUSION Although there was only one objective response, dasatinib is well tolerated, with tumor stabilization achieved by 50% of ACC patients. Dasatinib demonstrated no activity in non-ACC MSGT.
Collapse
Affiliation(s)
- S J Wong
- Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee
| | | | - D N Hayes
- University of North Carolina at Chapel Hill, Chapel Hill
| | - M S Kies
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston
| | - K J Cullen
- University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore
| | - T Tanvetyanon
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
| | - A Argiris
- Department of Medical Oncology, Hygeia Hospital, Athens, Greece University of Texas Health Science Center at San Antonio, San Antonio
| | - N Takebe
- Investigational Drug Branch, Cancer Therapy Evaluation Program, Rockville
| | - D Lim
- Department of Medicine, City of Hope, Duarte
| | - N F Saba
- Winship Cancer Institute, Emory University, Atlanta
| | - F P Worden
- Department of Medicine, University of Michigan Cancer Center, Ann Arbor
| | - J Gilbert
- Department of Hematology Oncology, Vanderbilt University, Nashville
| | - H J Lenz
- USC Norris Comprehensive Cancer Center, Los Angeles
| | - A R A Razak
- Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto
| | | | | | - E E W Cohen
- University of California San Diego, Moores Cancer Center, San Diego, USA
| |
Collapse
|
29
|
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 2015; 22:1067-75. [PMID: 26446942 DOI: 10.1158/1078-0432.ccr-15-1076] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Accepted: 09/06/2015] [Indexed: 12/19/2022]
Abstract
PURPOSE AZD6244 is a MEK1/2 inhibitor with significant preclinical activity in multiple myeloma cells. This phase II study used a two-stage Simon design to determine the AZD6244 response rate in patients with relapsed or refractory multiple myeloma. EXPERIMENTAL DESIGN AZD6244 (75 mg) was administered orally, twice a day, continuously for 28-day cycles. Response was evaluated after three cycles. RESULTS Thirty-six patients received therapy. The median age was 65 years (range: 43-81) and the median number of prior therapies was 5 (range: 2-11). The most common grade 3 and 4 toxicities included anemia, neutropenia, thrombocytopenia, diarrhea, and fatigue. Three deaths occurred possibly related to AZD6244 (2 due to sepsis, 1 due to acute kidney injury). After AZD6244 discontinuation, three additional deaths occurred due to disease progression. The response rate (CR + PR) was 5.6% with a mean duration of response of 4.95 months and median progression-free survival time of 3.52 months. One patient had a very good partial response (VGPR), 1 patient had a partial response, 17 patients had stable disease, 13 patients had progressive disease, and 4 patients could not be assessed for response. Pharmacodynamic studies revealed variable effects on bone marrow CD138(+) cell MEK1/2 and ERK1/2 phosphorylation. The best clinical response, a prolonged VGPR, occurred in a patient with an MMSET translocation. CONCLUSIONS Single-agent AZD6244 was tolerable and had minimal activity in this heavily pretreated population.
Collapse
Affiliation(s)
- Beata Holkova
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.
| | - Adriana Zingone
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Maciej Kmieciak
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
| | - Prithviraj Bose
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia
| | - Ashraf Z Badros
- Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
| | - Peter M Voorhees
- Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina
| | - Rachid Baz
- Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center, Tampa, Florida
| | - Neha Korde
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Hui-Yi Lin
- Department of Biostatistics and Biomedical Informatics, H. Lee Moffitt Cancer Center, Tampa, Florida
| | - Jin-Qiu Chen
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Michelle Herrmann
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Liqiang Xi
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Mark Raffeld
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Xiuhua Zhao
- Department of Biostatistics and Biomedical Informatics, H. Lee Moffitt Cancer Center, Tampa, Florida
| | - Wen Wan
- Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia
| | - Mary Beth Tombes
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
| | - Ellen Shrader
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
| | - Caryn Weir-Wiggins
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
| | - Heidi Sankala
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
| | - Kevin T Hogan
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
| | - Austin Doyle
- Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Christina M Annunziata
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Martha Wellons
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
| | - John D Roberts
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia
| | - Daniel Sullivan
- Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center, Tampa, Florida
| | - Ola Landgren
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Steven Grant
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia. Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, Virginia. Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia. Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, Virginia.
| |
Collapse
|
30
|
Poklepovic AS, Shafer DA, Roberts JD, Geyer CE, Dent P, Moran R, Tombes MB, Shrader E, Strickler K, Wan W. Phase I study of pemetrexed and sorafenib in advanced solid tumors. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.2586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Charles E. Geyer
- Virginia Commonwealth University Massey Cancer Center, Richmond, VA
| | - Paul Dent
- Virginia Commonwealth University Massey Cancer Center, Richmond, VA
| | - Richard Moran
- Virginia Commonwealth University Massey Cancer Center, Richmond, VA
| | - Mary Beth Tombes
- Virginia Commonwealth University Massey Cancer Center, Richmond, VA
| | - Ellen Shrader
- Virginia Commonwealth University Massey Cancer Center, Richmond, VA
| | | | - Wen Wan
- Virginia Commonwealth University Massey Cancer Center, Richmond, VA
| |
Collapse
|
31
|
Himelstein AL, Qin R, Novotny PJ, Seisler DK, Khatcheressian JL, Roberts JD, Grubbs SS, O'Connor T, Weckstein D, Loprinzi CL, Shapiro CL. CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.9501] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Rui Qin
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN
| | - Paul J. Novotny
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN
| | - Drew K. Seisler
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Smith WR, McClish DK, Dahman BA, Levenson JL, Aisiku IP, de A Citero V, Bovbjerg VE, Roberts JD, Penberthy LT, Roseff SD. Daily home opioid use in adults with sickle cell disease: The PiSCES project. J Opioid Manag 2015; 11:243-253. [PMID: 25985809 DOI: 10.5055/jom.2015.0273] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
BACKGROUND Although opioid prescribing in sickle cell disease (SCD) can be controversial, little is published about patterns of opioid use. OBJECTIVE To report on home opioid use among adults with SCD. DESIGN Cohort study. PARTICIPANTS Adults with SCD (n=219) who completed daily pain diaries for up to 6 months and had at least one home pain day. MAIN MEASURES Use of long-acting or short-acting opioids, other analgesics, or adjuvants; the proportion of home days, home pain days, and home crisis days with opioid use; these two outcomes according to patient characteristics. KEY RESULTS Patients used opioids on 12,311 (78 percent) of 15,778 home pain days. Eighty-five patients (38.8 percent) used long-acting opioids with or without short-acting opioids and 103 (47.0 percent) used only short-acting opioids. Twenty-one (9.6 percent) patients used only non-opioid analgesics and 10 (4.6 percent) used no analgesics. Both pain intensity and pain frequency were higher among opioid users (analysis of variance [ANOVA], p<0.0001). Opioid users used hydroxyurea more often than nonusers, even when controlling for mean pain on pain days. Among all patients, significant relationships were found between any opioid use and somatic symptom burden, SCD stress, negative coping, and physical and mental quality of life (QOL); the relationship with SCD stress and physical QOL remained when controlled for mean pain. Among opioid users, similar associations were found between frequency of opioid use and some disease-related and psychosocial variables. CONCLUSIONS In this adult SCD sample, opioids were used by the majority of patients. Pain was the overwhelming characteristic associated with use, but disease-related and psychosocial variables were also associated.
Collapse
Affiliation(s)
- Wally R Smith
- Florence Neal Cooper Smith Professor of Sickle Cell Disease, Division of General Internal Medicine, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia
| | - Donna K McClish
- Professor, Department of Biostatistics, School of Medicine, Virginia Commonwealth University, Richmond, Virginia
| | - Bassam A Dahman
- Assistant Professor, Healthcare Policy and Research, Virginia Commonwealth University, Richmond, Virginia
| | - James L Levenson
- Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia
| | - Imoigele P Aisiku
- Assistant Professor, Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts
| | - Vanessa de A Citero
- Dept. de Psiquiatria, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
| | - Viktor E Bovbjerg
- Associate Professor, College of Public Health and Human Sciences, Oregon State University, Corvallis, Oregon
| | - John D Roberts
- Professor, Section of Medical Oncology, Department of Medicine, Director, Yale Adult Sickle Cell Program, Smilow Cancer Hospital at Yale - New Haven, New Haven, Connecticut
| | - Lynne T Penberthy
- Associate Director, Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
| | - Susan D Roseff
- Chair, Division of Clinical Pathology, Department of Pathology, Virginia Commonwealth University, Richmond, Virginia
| |
Collapse
|
33
|
So DYF, Wells GA, McPherson R, Labinaz M, Le May MR, Glover C, Dick AJ, Froeschl M, Marquis JF, Gollob MH, Tran L, Bernick J, Hibbert B, Roberts JD. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J 2015; 16:71-8. [PMID: 25850030 DOI: 10.1038/tpj.2015.17] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2014] [Revised: 12/19/2014] [Accepted: 01/28/2015] [Indexed: 01/07/2023]
Abstract
Treatment of carriers of the CYP2C19*2 allele and ABCB1 TT genotype with clopidogrel is associated with increased ischemic complications after percutaneous coronary intervention (PCI). We sought to evaluate a pharmacogenomic strategy among patients undergoing PCI for ST-elevation myocardial infarction (STEMI), by performing a randomized trial, enrolling 102 patients. Point-of-care genetic testing for CYP2C19*2, ABCB1 TT and CYP2C19*17 was performed with carriers of either the CYP2C19*2 allele or ABCB1 TT genotype randomly assigned to a strategy of prasugrel 10 mg daily or an augmented dosing strategy of clopidogrel (150 mg daily for 6 days then 75 mg daily). The primary end point was the proportion of at-risk carriers exhibiting high on-treatment platelet reactivity (HPR), a marker associated with increased adverse cardiovascular events, after 1 month. Fifty-nine subjects (57.8%) were identified as carriers of at least one at-risk variant. Treatment with prasugrel significantly reduced HPR compared with clopidogrel by P2Y12 reaction unit (PRU) thresholds of >234 (0 vs 24.1%, P=0.0046) and PRU>208 (3.3 vs 34.5%, P=0.0025). The sensitivity of point-of-care testing was 100% (95% CI 88.0-100), 100% (86.3-100) and 96.9% (82.0-99.8) and specificity was 97.0% (88.5-99.5), 97.1% (89.0-99.5) and 98.5% (90.9-99.9) for identifying CYP2C19*2, ABCB1 TT and CYP2C19*17, respectively. Logistic regression confirmed carriers as a strong predictor of HPR (OR=6.58, 95% CI 1.24-34.92; P=0.03). We confirmed that concurrent identification of three separate genetic variants in patients with STEMI receiving PCI is feasible at the bedside. Among carriers of at-risk genotypes, treatment with prasugrel was superior to an augmented dosing strategy of clopidogrel in reducing HPR.
Collapse
Affiliation(s)
- D Y F So
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - G A Wells
- Cardiovascular Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - R McPherson
- Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - M Labinaz
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - M R Le May
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - C Glover
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - A J Dick
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - M Froeschl
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - J-F Marquis
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - M H Gollob
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - L Tran
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - J Bernick
- Cardiovascular Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - B Hibbert
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - J D Roberts
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| |
Collapse
|
34
|
Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor re-growth. Cancer Biol Ther 2014; 4:1275-84. [PMID: 16319524 DOI: 10.4161/cbt.4.11.2286] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Previous studies from our group have demonstrated in vitro that UCN-01 (7-hydroxystaurosporine) and inhibitors of MEK1/2 interact to cause tumor cell death in a wide variety of malignant, but not in nontransformed, cell types. The present studies determined whether UCN-01 and MEK1/2 inhibitors interacted to cause tumor cell death in vivo. In vitro colony formation studies demonstrated that UCN-01 and the MEK1/2 inhibitor PD184352 interacted to synergistically kill human mammary carcinoma cells (MDA-MB-231, MCF7) with similar combination index values. Athymic mice were implanted in the rear flank with either MDA-MB-231 or MCF7 cells and tumors permitted to form to a volume of approximately 100 mm3 prior to a two day exposure of either Vehicle, PD184352 (25 mg/kg), UCN-01 (0.1-0.2 mg/kg) or the drug combination. Tumor volume was measured every other day and tumor growth determined over the following approximately 30 days. Transient exposure of MDA-MB-231 tumors or MCF7 tumors to either PD184352 or UCN-01 did not significantly alter tumor growth rate or the mean tumor volume in vivo approximately 15-30 days after drug administration. In contrast, combined treatment with PD184352 and UCN-01 significantly reduced MDA-MB-231, and largely abolished MCF7 tumor growth. Tumor control values for both cell lines were 0.36. Tumor cells isolated approximately 30 days after combined drug exposure exhibited a significantly greater reduction in plating efficiency using ex vivo colony formation assays than tumor cells that were exposed to either drug individually. Reduced tumor growth correlated with profound tumor cell death within five days of combined drug exposure, which was also evident approximately 30 days after exposure. In addition, tumor cell death correlated with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. Collectively, these findings argue that UCN-01 and MEK1/2 inhibitors have the potential to suppress mammary tumor growth in vivo which is independent of p53 status, estrogen dependency, caspase 3 levels or oncogenic K-RAS expression.
Collapse
Affiliation(s)
- William Hawkins
- Department of Biochemistry, Virginia Commonwealth University, Richmond, Virginia 23298-0058, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 2014; 20:5652-62. [PMID: 25248382 DOI: 10.1158/1078-0432.ccr-14-0805] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE This phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the combination of bortezomib and alvocidib in patients with B-cell malignancies (multiple myeloma, indolent lymphoma, Waldenstrom macroglobulinemia, and mantle cell lymphoma). EXPERIMENTAL DESIGN Patients received bortezomib (intravenous push), followed by alvocidib (1-hour infusion), on days 1, 4, 8, and 11 of a 21-day treatment cycle. Patients experiencing responses or stable disease continued on treatment at the investigator's discretion. A standard 3+3 dose-escalation design was used to identify the MTD based on DLTs, and pharmacokinetic and pharmacodynamic studies were conducted. RESULTS A total of 44 patients were enrolled, with 39 patients assessed for response. The MTD was established as 1.3 mg/m(2) for bortezomib and 40 mg/m(2) for alvocidib. The most common hematologic toxicities included leukopenia, lymphopenia, neutropenia, and thrombocytopenia. The most common nonhematologic toxicities included diarrhea, fatigue, and sensory neuropathy. Three complete remissions (8%) and 10 partial remissions (26%) were observed for a total response rate of 33%. Pharmacokinetic findings with the current dosing regimen were consistent with the comparable literature and the hybrid dosing regimen. Pharmacodynamic study results did not correlate with clinical responses. CONCLUSIONS The combination of bortezomib and alvocidib is tolerable, and an MTD has been established for this schedule. The regimen appears to be efficacious in patients with relapsed/refractory multiple myeloma or indolent non-Hodgkin lymphoma. As the nonhybrid regimen is less cumbersome than the previous hybrid dosing schedule regimen, the current schedule is recommended for successor studies.
Collapse
Affiliation(s)
- Beata Holkova
- Massey Cancer Center and Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.
| | | | - E Brent Perkins
- Massey Cancer Center and Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia
| | - Prithviraj Bose
- Massey Cancer Center and Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia
| | - Rachid C Baz
- Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
| | - G David Roodman
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Robert K Stuart
- Department of Medicine, Medical University of South Carolina, Charleston, South Carolina
| | | | - Wen Wan
- Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia
| | - Cody J Peer
- Center for Cancer Research, NCI, NIH, Bethesda, Maryland
| | - Jana Dawson
- Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
| | | | | | | | | | | | | | | | | | - A Dimitrios Colevas
- Cancer Therapy Evaluation Program, NCI, NIH, Bethesda, Maryland. Departments of
| | - L Austin Doyle
- Cancer Therapy Evaluation Program, NCI, NIH, Bethesda, Maryland. Departments of
| | - William D Figg
- Center for Cancer Research, NCI, NIH, Bethesda, Maryland
| | - Domenico Coppola
- Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
| | - John D Roberts
- Massey Cancer Center and Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia
| | - Daniel Sullivan
- Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
| | - Steven Grant
- Massey Cancer Center and Massey Cancer Center and Massey Cancer Center and Massey Cancer Center and Massey Cancer Center and
| |
Collapse
|
36
|
Lai HWH, Liu AT, Emenike BU, Carroll WR, Roberts JD. Conformational preferences of N,N-dimethylsuccinamate as a function of alkali and alkaline earth metal salts: experimental studies in DMSO and water as determined by 1H NMR spectroscopy. J Phys Chem A 2014; 118:1965-70. [PMID: 24506581 PMCID: PMC3983401 DOI: 10.1021/jp4106508] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The fraction of gauche conformers of N,N-dimethylsuccinamic acid (1) and its Li(+), Na(+), K(+), Mg(2+), Ca(2+), and N(Bu)4(+) salts were estimated in DMSO and D2O solution by comparing the experimental vicinal proton-proton couplings determined by (1)H NMR spectroscopy with those calculated using the Haasnoot, de Leeuw, and Altona (HLA) equation. In DMSO, the gauche preferences were found to increase with decreasing Ahrens ionic radius of the metal counterion. The same trend was not seen in D2O, where the gauche fraction for all of the metallic salts were estimated to be approximately statistical or less. This highlights the importance of metal chelation on the conformation of organic molecules in polar aprotic media, which has implications for protein folding.
Collapse
Affiliation(s)
- Holden W H Lai
- Gates and Crellin Laboratories of Chemistry, California Institute of Technology , Pasadena, California 91125, United States
| | | | | | | | | |
Collapse
|
37
|
Emenike BU, Liu AT, Naveo EP, Roberts JD. Substituent Effects on Energetics of Peptide-Carboxylate Hydrogen Bonds as Studied by 1H NMR Spectroscopy: Implications for Enzyme Catalysis. J Org Chem 2013; 78:11765-71. [DOI: 10.1021/jo401762m] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Bright U. Emenike
- Gates and Crellin Laboratories
of Chemistry, California Institute of Technology, Pasadena, California 91125
| | - Albert Tianxiang Liu
- Gates and Crellin Laboratories
of Chemistry, California Institute of Technology, Pasadena, California 91125
| | - Elsy P. Naveo
- Gates and Crellin Laboratories
of Chemistry, California Institute of Technology, Pasadena, California 91125
| | - John D. Roberts
- Gates and Crellin Laboratories
of Chemistry, California Institute of Technology, Pasadena, California 91125
| |
Collapse
|
38
|
Liu AT, Nag M, Carroll WR, Roberts JD. Conformational analysis of N,N,N-Trimethyl-(3,3-dimethylbutyl)ammonium iodide by NMR spectroscopy: a sterically hindered trans-standard. Magn Reson Chem 2013; 51:701-704. [PMID: 25940961 DOI: 10.1002/mrc.4003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2013] [Revised: 08/01/2013] [Accepted: 08/03/2013] [Indexed: 06/04/2023]
Abstract
A predominantly trans-1,2-disubstituted ethane system - N,N,N-trimethyl-(3,3-dimethylbutyl)ammonium iodide - is of particular interest for conformational analysis, because it contains both an organic and a highly polar substituent, making it soluble and thus applicable to study in a large variety of solvents. The fraction of the trans conformer of this molecule in a wide range of protic and aprotic solvents was determined by the nuclear magnetic resonance proton couplings to be approximately 90%, in contrast to the previously assumed 100%. The consistently strong preference of the trans conformation should establish N,N,N-trimethyl-(3,3-dimethylbutyl)ammonium iodide as a possibly useful 'trans-standard' in conformational analysis, much more so than 1,2-ditert-butylethane, which has a poor solubility in many solvents.
Collapse
Affiliation(s)
- Albert Tianxiang Liu
- Gates and Crellin Laboratories of Chemistry, California Institute of Technology, Pasadena, California, 91125
| | | | | | | |
Collapse
|
39
|
George MD, Wine RN, Lackford B, Kissling GE, Akiyama SK, Olden K, Roberts JD. p38 mitogen-activated protein kinase interacts with vinculin at focal adhesions during fatty acid-stimulated cell adhesion. Biochem Cell Biol 2013; 91:404-18. [PMID: 24219282 DOI: 10.1139/bcb-2013-0013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Arachidonic acid stimulates cell adhesion by activating α2β1 integrins in a process that depends on protein kinases, including p38 mitogen activated protein kinase. Here, we describe the interaction of cytoskeletal components with key signaling molecules that contribute to the spreading of, and morphological changes in, arachidonic acid-treated MDA-MB-435 human breast carcinoma cells. Arachidonic acid-treated cells showed increased attachment and spreading on collagen type IV, as measured by electric cell-substrate impedance sensing. Fatty acid-treated cells displayed short cortical actin filaments associated with an increased number of β1 integrin-containing pseudopodia, whereas untreated cells displayed elongated stress fibers and fewer clusters of β1 integrins. Confocal microscopy of arachidonic acid-treated cells showed that vinculin and phospho-p38 both appeared enriched in pseudopodia and at the tips of actin filaments, and fluorescence ratio imaging indicated the increase was specific for the phospho-(active) form of p38. Immunoprecipitates of phospho-p38 from extracts of arachidonic acid-treated cells contained vinculin, and GST-vinculin fusion proteins carrying the central region of vinculin bound phospho-p38, whereas fusion proteins expressing the terminal portions of vinculin did not. These data suggest that phospho-p38 associates with particular domains on critical focal adhesion proteins that are involved in tumor cell adhesion and spreading, and that this association can be regulated by factors in the tumor microenvironment.
Collapse
Affiliation(s)
- Margaret D George
- National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA
| | | | | | | | | | | | | |
Collapse
|
40
|
Wong SJ, Cohen EE, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE. A phase II study of dasatanib (BMS 354825) in recurrent or metastatic ckit-expressing adenoid cystic (ACC) and non-ACC malignant salivary glands tumors (MSGT). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.6022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6022 Background: ACC is a rare disease, accounting for 1/3rd of MSGT, in which 90% of cases express the protein product of the ckit proto-oncogene. Dasatinib is a potent and selective inhibitor of five oncogenic PTKs/kinase families including ckit. We conducted a phase II study to determine the antitumor activity of dasatinib in ACC and non-ACC MSGT. Methods: In a two-stage design, adult patients (pts) with recent radiographic progressive, recurrent or metastatic ACC, + cKIT, were treated with dasatinib 70 mg PO BID. Pts with non-ACC MSGT of other histologic types, were treated as a separate cohort. Response was assessed every 8 wks by imaging using RECIST criteria. The study design stipulated enrollment of n=40 ACC patients (20 in stage I and 20 in stage II) and 25 non-ACC patients (14 in stage I and 11 in stage II). Results: Fifty-four pts were enrolled, 40 ACC and 14 non-ACC. One additional pt was a screen failure. Baseline data on 54 pts are: M:F = 28:26, median age 56.6 yrs (range 20-82), PS 0:1:2 = 24:28:2, prior radiation:chemotherapy = 44:21. The most frequent adverse events experienced (as % of pts, worst grade 2 or higher and at least possibly related to study drug) were: fatigue (28%), nausea (19%), headache (15%), lymphopenia (11%), dyspnea (11%), alanine aminotransferase increased (7%), anorexia (7%), vomiting (7%), alkaline phosphatase increased (6%), diarrhea (6%), and non-cardiac chest pain (6%). No grade 4 adverse events occurred and only 15 pts experienced a grade 3 adverse event (at least possibly attributed to study drug), primarily dyspnea (4 patients) and fatigue (3 patients). Significant cardiac toxicity was observed in one pt (grade 3 prolonged QT corrected interval). Among ACC pts, best response to dasatinib: 0 pts (0%) had PR, 21 pts (52%) had SD (range 2.8-13.8 months), 12 pts (30%) had PD, and 2 died prior to cycle 2. Median PFS was 4.8 mos. For 14 evaluable non-ACC pts, none had an objective response, triggering early stopping. 7 had SD (range 1.4-6.6 months), and 4 PD. Conclusions: Although there were no objective responses, dasatinib is well tolerated, with tumor stabilization achieved by 52% of ACC pts. Dasatinib demonstrated no activity in non-ACC MSGT. Clinical trial information: NCT00859937.
Collapse
Affiliation(s)
| | - Ezra E.W. Cohen
- The University of Chicago Medicine and Biological Sciences, Chicago, IL
| | | | - David N. Hayes
- Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - Merrill S. Kies
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Kevin J. Cullen
- University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD
| | | | | | - Naoko Takebe
- Investigational Drug Branch, Cancer Therapy Evaluation Program, Rockville, MD
| | | | - Nabil F. Saba
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
| | | | | | - Heinz-Josef Lenz
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
| | | | | | - Everett E. Vokes
- The University of Chicago Medicine and Biological Sciences, Chicago, IL
| |
Collapse
|
41
|
Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res 2013; 19:1873-83. [PMID: 23515411 DOI: 10.1158/1078-0432.ccr-12-2926] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
PURPOSE This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Secondary objectives included investigating the pharmacokinetic and pharmacodynamic effects of the combination. EXPERIMENTAL DESIGN Patients received vorinostat (200 mg orally, three times a day, for 14 days) on a 21-day cycle, combined with 2 different alvocidib administration schedules: a 1-hour intravenous infusion, daily × 5; or a 30-minute loading infusion followed by a 4-hour maintenance infusion, weekly × 2. The alvocidib dose was escalated using a standard 3+3 design. RESULTS Twenty-eight patients were enrolled and treated. The alvocidib MTD was 20 mg/m(2) (30-minute loading infusion) followed by 20 mg/m(2) (4-hour maintenance infusion) on days one and eight, in combination with vorinostat. The most frequently encountered toxicities were cytopenias, fatigue, hyperglycemia, hypokalemia, hypophosphatemia, and QT prolongation. Dose-limiting toxicities (DLT) were cardiac arrhythmia-atrial fibrillation and QT prolongation. No objective responses were achieved although 13 of 26 evaluable patients exhibited stable disease. Alvocidib seemed to alter vorinostat pharmacokinetics, whereas alvocidib pharmacokinetics were unaffected by vorinostat. Ex vivo exposure of leukemia cells to plasma obtained from patients after alvocidib treatment blocked vorinostat-mediated p21(CIP1) induction and downregulated Mcl-1 and p-RNA Pol II for some specimens, although parallel in vivo bone marrow responses were infrequent. CONCLUSIONS Alvocidib combined with vorinostat is well tolerated. Although disease stabilization occurred in some heavily pretreated patients, objective responses were not obtained with these schedules.
Collapse
Affiliation(s)
- Beata Holkova
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Liu AT, Emenike BU, Carroll WR, Roberts JD. Conformational equilibria of N,N-dimethylsuccinamic acid and its lithium salt as a function of solvent. Org Lett 2013; 15:760-3. [PMID: 23363019 DOI: 10.1021/ol302573b] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The conformational preferences of N,N-dimethylsuccinamic acid and its Li(+) salt were estimated by comparing the respective experimental NMR vicinal proton-proton coupling constants to semiempirical coupling constants for each staggered conformer as derived by the Haasnoot-De Leeuw-Altona method. The strong gauche preferences for the Li(+) salts clearly depended more on the solvents' hydrogen-bond donating strength (α) than on their hydrogen-bond accepting (β) counterpart, where α and β are the corresponding Kamlet-Taft parameters.
Collapse
Affiliation(s)
- Albert Tianxiang Liu
- Gates and Crellin Laboratories of Chemistry, California Institute of Technology, Pasadena, California 91125, United States
| | | | | | | |
Collapse
|
43
|
Emenike BU, Carroll WR, Roberts JD. Conformational Preferences of cis-1,3-Cyclopentanedicarboxylic Acid and Its Salts by 1H NMR Spectroscopy: Energetics of Intramolecular Hydrogen Bonds in DMSO. J Org Chem 2013; 78:2005-11. [DOI: 10.1021/jo302049z] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Bright U. Emenike
- Gates and Crellin Laboratories of
Chemistry, California Institute of Technology, Pasadena, California
91125, United States
| | - William R. Carroll
- Gates and Crellin Laboratories of
Chemistry, California Institute of Technology, Pasadena, California
91125, United States
| | - John D. Roberts
- Gates and Crellin Laboratories of
Chemistry, California Institute of Technology, Pasadena, California
91125, United States
| |
Collapse
|
44
|
Silla AJ, Roberts JD. Investigating patterns in the spermiation response of eight Australian frogs administered human chorionic gonadotropin (hCG) and luteinizing hormone-releasing hormone (LHRHa). Gen Comp Endocrinol 2012; 179:128-36. [PMID: 22909973 DOI: 10.1016/j.ygcen.2012.08.009] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2012] [Revised: 07/27/2012] [Accepted: 08/05/2012] [Indexed: 10/28/2022]
Abstract
Exogenous LHRHa and hCG are routinely employed to induce spermiation in vivo in anurans. To date, however, few studies have directly compared the efficacy of these two hormones. The aim of this study was threefold. First to quantify the spermiation response of eight Australian anuran species (Crinia glauerti, Crinia georgiana, Crinia pseudinsignifera, Geocrinia rosea, Heleioporus albopunctatus, Heleioporuseyrei, Neobatrachus pelobatoides and Pseudophryne guentheri) administered LHRHa and hCG. Second, to determine whether variance in spermiation responses is related to a species' reproductive mode (aquatic vs. terrestrial) or family (Limnodynastidae vs. Myobatrachidae). Third, to compare the quantity and quality of spermatozoa obtained via hormone administration (LHRHa and hCG) to spermatozoa obtained via testis removal and maceration. There was no significant difference in the viability of spermatozoa obtained from hCG or LHRHa administration in any of the eight study species. The sperm viability of samples ranged from 28-84% in C. georgiana and G. rosea, respectively. The hormone that induced the release of the highest number of spermatozoa differed among species, with all five species belonging to the family Myobatrachidae responding better to LHRHa, and the three species from the family Lymnodynastidae releasing a greater number of spermatozoa in response to hCG. Importantly, these results provide the first preliminary evidence that hCG and LHRHa efficacy in anurans may be predicted by phylogeny. Understanding such broad-scale patterns in the response of anurans to exogenous hormones will expedite the application of assisted reproductive technologies to novel species.
Collapse
Affiliation(s)
- Aimee J Silla
- School of Animal Biology, The University of Western Australia, Perth, Australia.
| | | |
Collapse
|
45
|
Roberts JD, Herkert JC, Rutberg J, Nikkel SM, Wiesfeld ACP, Dooijes D, Gow RM, van Tintelen JP, Gollob MH. Detection of genomic deletions ofPKP2in arrhythmogenic right ventricular cardiomyopathy. Clin Genet 2012; 83:452-6. [DOI: 10.1111/j.1399-0004.2012.01950.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2012] [Revised: 08/07/2012] [Accepted: 08/07/2012] [Indexed: 11/27/2022]
Affiliation(s)
- JD Roberts
- Inherited Arrhythmia Clinic and the Arrhythmia Research Laboratory; University of Ottawa Heart Institute; Ottawa; Ontario; Canada
| | - JC Herkert
- Department of Genetics, University Medical Center Groningen; University of Groningen; Groningen; the Netherlands
| | - J Rutberg
- Inherited Arrhythmia Clinic and the Arrhythmia Research Laboratory; University of Ottawa Heart Institute; Ottawa; Ontario; Canada
| | - SM Nikkel
- Department of Pediatrics, The Children's Hospital of Eastern Ontario; University of Ottawa; Ottawa; Ontario; Canada
| | - ACP Wiesfeld
- Department of Cardiology, University Medical Center Groningen; University of Groningen; Groningen; the Netherlands
| | - D Dooijes
- Department of Medical Genetics; University Medical Center Utrecht; Utrecht; the Netherlands
| | - RM Gow
- Division of Cardiology, Inherited Arrhythmia Clinic; The Childrens Hospital of Eastern Ontario; Ottawa; Ontario; Canada
| | - JP van Tintelen
- Department of Genetics, University Medical Center Groningen; University of Groningen; Groningen; the Netherlands
| | - MH Gollob
- Inherited Arrhythmia Clinic and the Arrhythmia Research Laboratory; University of Ottawa Heart Institute; Ottawa; Ontario; Canada
| |
Collapse
|
46
|
Garza AJ, Nag M, Carroll WR, Goddard WA, Roberts JD. Conformational Preferences of trans-1,2- and cis-1,3-Cyclohexanedicarboxylic Acids in Water and Dimethyl Sulfoxide as a Function of the Ionization State As Determined from NMR Spectroscopy and Density Functional Theory Quantum Mechanical Calculations. J Am Chem Soc 2012; 134:14772-80. [DOI: 10.1021/ja302133s] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Alejandro J. Garza
- Crellin
Laboratory of Chemistry and ‡Materials and Process Simulation Center, California Institute of Technology,
Pasadena, California 91125, United States
| | - Mrinmoy Nag
- Crellin
Laboratory of Chemistry and ‡Materials and Process Simulation Center, California Institute of Technology,
Pasadena, California 91125, United States
| | - William R. Carroll
- Crellin
Laboratory of Chemistry and ‡Materials and Process Simulation Center, California Institute of Technology,
Pasadena, California 91125, United States
| | - William A. Goddard
- Crellin
Laboratory of Chemistry and ‡Materials and Process Simulation Center, California Institute of Technology,
Pasadena, California 91125, United States
| | - John D. Roberts
- Crellin
Laboratory of Chemistry and ‡Materials and Process Simulation Center, California Institute of Technology,
Pasadena, California 91125, United States
| |
Collapse
|
47
|
Herwig JN, Depczynski M, Roberts JD, Semmens JM, Gagliano M, Heyward AJ. Using age-based life history data to investigate the life cycle and vulnerability of Octopus cyanea. PLoS One 2012; 7:e43679. [PMID: 22912898 PMCID: PMC3422261 DOI: 10.1371/journal.pone.0043679] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2012] [Accepted: 07/26/2012] [Indexed: 12/02/2022] Open
Abstract
Octopus cyanea is taken as an unregulated, recreationally fished species from the intertidal reefs of Ningaloo, Western Australia. Yet despite its exploitation and importance in many artisanal fisheries throughout the world, little is known about its life history, ecology and vulnerability. We used stylet increment analysis to age a wild O. cyanea population for the first time and gonad histology to examine their reproductive characteristics. O. cyanea conforms to many cephalopod life history generalisations having rapid, non-asymptotic growth, a short life-span and high levels of mortality. Males were found to mature at much younger ages and sizes than females with reproductive activity concentrated in the spring and summer months. The female dominated sex-ratios in association with female brooding behaviours also suggest that larger conspicuous females may be more prone to capture and suggests that this intertidal octopus population has the potential to be negatively impacted in an unregulated fishery. Size at age and maturity comparisons between our temperate bordering population and lower latitude Tanzanian and Hawaiian populations indicated stark differences in growth rates that correlate with water temperatures. The variability in life history traits between global populations suggests that management of O. cyanea populations should be tailored to each unique set of life history characteristics and that stylet increment analysis may provide the integrity needed to accurately assess this.
Collapse
Affiliation(s)
- Jade N. Herwig
- The Oceans Institute, University of Western Australia, Perth, Western Australia, Australia
| | - Martial Depczynski
- The Oceans Institute, University of Western Australia, Perth, Western Australia, Australia
- Australian Institute of Marine Science, The Oceans Institute, University of Western Australia, Perth, Western Australia, Australia
- * E-mail:
| | - John D. Roberts
- Centre for Evolutionary Biology, School of Animal Biology, The University of Western Australia, Perth, Western Australia, Australia
| | - Jayson M. Semmens
- Institute for Marine and Antarctic Research, Fisheries, Aquaculture and Coasts Centre, University of Tasmania, Hobart, Tasmania, Australia
| | - Monica Gagliano
- Centre for Evolutionary Biology, School of Animal Biology, The University of Western Australia, Perth, Western Australia, Australia
- Centre for Microscopy, Characterisation and Analysis, The University of Western Australia, Perth, Western Australia, Australia
| | - Andrew J. Heyward
- The Oceans Institute, University of Western Australia, Perth, Western Australia, Australia
- Australian Institute of Marine Science, The Oceans Institute, University of Western Australia, Perth, Western Australia, Australia
| |
Collapse
|
48
|
Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Figg WD, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol 2012; 69:1657-67. [PMID: 22349810 PMCID: PMC3365614 DOI: 10.1007/s00280-012-1839-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2011] [Accepted: 01/29/2012] [Indexed: 11/24/2022]
Abstract
PURPOSE Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl(+) malignancies. METHODS In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1 h intravenous infusion weekly for 3 weeks every 4 weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome-positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed. RESULTS A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30 months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed. CONCLUSIONS This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.
Collapse
Affiliation(s)
- Prithviraj Bose
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
- Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA
| | - Edward B Perkins
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
- Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA
| | - Connie Honeycut
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
| | - Martha D Wellons
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
| | - Tammy Stefan
- Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
| | - James W Jacobberger
- Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
| | - Emmanouil Kontopodis
- Department of Medical Oncology, University Hospital of Heraklion, Greece
- Molecular Therapeutics/Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - Jan H Beumer
- Molecular Therapeutics/Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA
- Melanoma Programs, University of Pittsburgh Cancer Institute, Pittsburgh, PA
- Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA
| | - Merrill J Egorin
- Molecular Therapeutics/Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA
- Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
- Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Chiyo K Imamura
- Department of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, Tokyo, Japan
| | - W Douglas Figg
- Molecular Pharmacology Section and Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute/National Institutes of Health, Bethesda, MD
| | - Judith E Karp
- Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
| | - Omer N Koc
- Department of Regional Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
| | - Brenda W Cooper
- Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
| | - Selina M Luger
- Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA
| | | | - John D Roberts
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
- Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA
| | - Steven Grant
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
- Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA
- Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA
- Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA
- The Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA
| |
Collapse
|
49
|
Ray DM, Myers PH, Painter JT, Hoenerhoff MJ, Olden K, Roberts JD. Inhibition of transforming growth factor-β-activated kinase-1 blocks cancer cell adhesion, invasion, and metastasis. Br J Cancer 2012; 107:129-36. [PMID: 22644295 PMCID: PMC3389413 DOI: 10.1038/bjc.2012.214] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Tumour cell metastasis involves cell adhesion and invasion, processes that depend on signal transduction, which can be influenced by the tumour microenvironment. N-6 polyunsaturated fatty acids, found both in the diet and in response to inflammatory responses, are important components of this microenvironment. METHODS We used short hairpin RNA (shRNA) knockdown of TGF-β-activated kinase-1 (TAK1) in human tumour cells to examine its involvement in fatty acid-stimulated cell adhesion and invasion in vitro. An in vivo model of metastasis was developed in which cells, stably expressing firefly luciferase and either a control shRNA or a TAK1-specific shRNA, were injected into the mammary fat pads of mice fed diets, rich in n-6 polyunsaturated fatty acids. Tumour growth and spontaneous metastasis were monitored with in vivo and in situ imaging of bioluminescence. RESULTS Arachidonic acid activated TAK1 and downstream kinases in MDA-MB-435 breast cancer cells and led to increased adhesion and invasion. Knockdown of TAK1 blocked this activation and inhibited both cell adhesion and invasion in vitro. Tumour growth at the site of injection was not affected by TAK1 knockdown, but both the incidence and extent of metastasis to the lung were significantly reduced in mice injected with TAK1 knockdown cells compared with mice carrying control tumour cells. CONCLUSION These data demonstrate the importance of TAK1 signalling in tumour metastasis in vivo and suggest an opportunity for antimetastatic therapies.
Collapse
Affiliation(s)
- D M Ray
- Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, Mail Drop D2-05, Room D248A, Rall Building, 111T. W. Alexander Drive, Research Triangle Park, NC 27709, USA
| | | | | | | | | | | |
Collapse
|
50
|
Roberts JD, Ramakrishnan V. Abstract 764: Multiple testing in a phase II trial design for the detection of tumor subtypes. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Tumor subtypes may be especially responsive to a particular treatment. Phase II designs that incorporate tumor subtypes typically require prospective tumor subtyping and stratified patient enrollment. These features are cumbersome, discourage patient and investigator participation, and select for patients with relatively indolent disease who can wait for subtyping results. Previously we described a two stage phase II design that permits tumor subtyping at the end of stage 1 and that does not require stratified enrollment (Clin Cancer Res 2011;17:5538). In this design results from stage 1 are used to select an appropriate stage 2 objective. The stage 2 objective may be either to estimate the response rate of either the tumor or a subtype or a formal test of the hypothesis that the response rate for a subtype is greater than the overall response rate. Previously, although our design accommodated multiple subtypes in stage 1, it allowed further testing of only a single subtype in stage 2. Here we expand upon the previous design by describing a method to evaluate multiple tumor subtypes in stage 2 with appropriate adjustments for multiple testing. As there are practical limits on sample size, these adjustments tend to reduce power. We identify strategies to limit loss of power by taking advantage of tumor biology. For example, when tumor subtypes are mutually exclusive or nested, some comparisons can be made without further “alpha spending”. We explore the promise of our approach for the efficient identification of clinically significant tumor subtypes more responsive to a specific targeted therapy.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 764. doi:1538-7445.AM2012-764
Collapse
|